Markets and Recent Developments in Medical Technologies, from MedMarket Diligence, LLC

Stroke, Parkinson's, Alzheimer's and other neuro applications making big advance in development of cell/tissue therapies, according to MedMarket Diligence report

pjd@mediligence.com (Patrick Driscoll) — Wed, 21 Apr 2010 07:23:19 -0700

Stroke and other cerebrovascular conditions, Parkinson's, Alzheimer's, epilepsy, traumatic brain injury and others constitute an annual neurology patient population of 15 million annually. To varying degrees, all of these are the subject of technology development by companies in the fields of cell therapy and tissue engineering. While cell and tissue technologies have had their first, best impact on skin/integumentary and orthopedic applications, the sciences of stem and other pluripotent cell therapy and tissue engineering are advancing rapidly, stimulating the commercial development of these therapies into more acute conditions like cardiovascular. Companies are equally aggressively developing applications in neurology.

The advanced medical technologies blog highlights efforts of companies in cell/tissue technologies toward neurology applications, with data drawn from the 2010 MedMarket Diligence Report, "Tissue Engineering, Cell Therapy and Transplantation Worldwide, 2009-2018."

A recognized leader in the field is Medtronic. See current market shares of cell/tissue manufacturers in neurology:

The MedMarket Diligence report is available online for immediate download or may be ordered via link.

Cell Therapy, Tissue Engineering Driving New Clinical Practices in $6.9 Billion Market (MMD report)

pjd@mediligence.com (Patrick Driscoll) — Mon, 5 Apr 2010 09:45:41 -0700

Treatments via cell therapy and tissue engineering constitute a $6.9 billion worldwide market as they have become a major thrust of new clinical practices in nearly all major medical specialties, according to a new MedMarket Diligence report.

The use of stem cells, allografts, autografts and other cell and tissue types for the treatment of disorders and conditions has succeeded from a clinical standpoint for their ability to be rapidly accepted by the human body and their specificity to the disease state. This has been most clearly the case in orthopedics and skin/integumentary treatments, where the practice of bone, ligament, cartilage, skin and other tissue repair practices have driven the creation of a current $6 billion market. However, acute care applications -- in cardiology, cancer, neurology and other clinical areas have become established and will help drive the aggregate global cell/tissue market to nearly $32 billion in less than ten years, according to a new MedMarket Diligence report. (See link.)

See the press release.

The report may be purchased online for immediate download or may be ordered via faxed order form at link.

Replacement of tissues and organs in clinical practice

pjd@mediligence.com (Patrick Driscoll) — Wed, 31 Mar 2010 09:58:38 -0700

A current $6.9 billion global market for cell therapy and tissue engineering is comprised of a significant volume of activity in the replacement of diseased and traumatized tissue. While much of this existing business is in skin/integumentary, orthopedic and dental/oral applications, representing either chronic or, certainly, less acute conditions, a growing amount of development and active marketing is taking place in more acute areas of healthcare including cardiovascular applications.

The advanced medical technologies blog of MedMarket Diligence details these cardiovascular applications, with data drawn from the MedMarket Diligence Report #S520, "Tissue Engineering and Cell Therapy Worldwide 2009-2018."

Global market size and growth of tissue engineering, cell therapy in U.S., Europe, Asia/Pacific and Rest of World

pjd@mediligence.com (Patrick Driscoll) — Tue, 16 Mar 2010 07:23:18 -0700

Growth in technology and market development of cell therapy and tissue engineering technologies is occurring at variable rates in different parts of the world, but in all cases the growth is more than robust. The advanced medical technologies blog of MedMarket Diligence illustrates the market impact of regional drivers and limiters.

Data is drawn from the MedMarket Diligence Report #S520, "Tissue Engineering and Cell Therapy Worldwide 2009-2018."

Orthopedic and skin tissue engineering and cell therapy developments

pjd@mediligence.com (Patrick Driscoll) — Tue, 2 Mar 2010 13:30:49 -0800

With early markets for cell therapy and tissue engineering being best represented by clinical applications in orthopedics and skin/integumentary, a sampling of technologies at various states of development within each is worth considering for insights into likely near-term market impact.

The advanced medical technologies blog details products and technologies at the development, preclinical and clinical trial stage for use in orthopedics and skin/integumentary treatments. Data is drawn from the MedMarket Diligence Report #S520, "Tissue Engineering and Cell Therapy Worldwide 2009-2018."

Cardiovascular and vascular applications of cell therapy and tissue engineering

pjd@mediligence.com (Patrick Driscoll) — Mon, 22 Feb 2010 14:48:14 -0800

Many companies have active initiatives in the development of cardiovascular and vascular cell therapies and tissue engineering, with products at the various stages of developmental/preclinical, clinical and even a handful of approved/marketed.

A new MedMarket Diligence report on "Tissue Engineering and Cell Therapy Worldwide" details the success in technology development and clinical practice for products in use in cardiovascular and vascular applications, as well as the spectrum of clinical areas in the global market.

See the February 2010 MedMarket Diligence report #S520, "Tissue Engineering and Cell Therapy Worldwide."

Markets and products proliferating in bone, cartilage, soft tissue and other cell/tissue products in orthopedics and spine in the accelerating industry of cell therapy and tissue engineering

pjd@mediligence.com (Patrick Driscoll) — Thu, 18 Feb 2010 07:24:25 -0800

The approved uses of cell and tissue technologies in orthopedics are multiplying as products of many types, materials, functions and forms become a part of routine clinical practice:

Tissue and cell types currently marketed by a number of companies include bone grafts, bone substitutes, soft tissue reinforcements, autologous cell-based therapies, allografts, cartilage repair, graft extenders/substitutes, bone augmentation , meniscus implant, allograft plugs and others.

The materials employed include biodegradable materials, biomaterials, scaffolds and other cellular matrices for cell seeding, biomaterials mimicking cancellous bone, and others.

The functions provided by these products include for guided tissue regeneration, replacement, anti-adhesion, repair and regeneration of cartilage, reconstruction of the spine, reconstruction of the pelvis, filling bone void, dermal filler, craniomaxillofacial surgery, and chondral and subchondral lesion repair.

Products may come in many forms such as gel, paste, solids (pins), polymer implants, anchors and others for bone and soft tissue applications in orthopedics, musculoskeletal, spine, dental, oral, maxillofacial and other applications.

A robust and growing number of companies is active in marketing these products, including Biocomposites, Biocoral, Biomet, Biomimetic Therapeutics, BioSyntech, BioTissue Technologies, co.don, ConMed Linvatec Biomaterials, DePuy, Exactech, Fidia Advanced Biopolymers (Anika Therapeutics), Forticell Bioscience, Genzyme Biosurgery, Inion, Integra Lifesciences, ISTO Technologies, Kensey Nash, LifeCell (KCI), Medtronic, Musculoskeletal Transplant Foundation, Organogenesis, Orthovita, Osteotech, ReGen Biologics, RTI Biologics, Serica Technologies (Allergan), Smith & Nephew, SpineSmith, Stryker, Synovis Life Technologies, TEI Biosciences, TiGenix and Zimmer.

A new MedMarket Diligence report on "Tissue Engineering and Cell Therapy Worldwide" details the success in technology development and clinical practice for products in use in orthopedics as well as the spectrum of clinical areas in the global market.

See the February 2010 MedMarket Diligence report #S520, "Tissue Engineering and Cell Therapy Worldwide."

Tissue Engineering & Cell Therapy: The $6.9 Billion Market, According to MedMarket Diligence Report

pjd@mediligence.com (Patrick Driscoll) — Tue, 16 Feb 2010 12:40:00 -0800

A new MedMarket Diligence report on "Tissue Engineering and Cell Therapy Worldwide" details the success in technology development and clinical practice for products in use across a spectrum of clinical areas in the global market.

Tissue engineering and cell therapy comprise a market for regenerative products that is expected to grow in the United States from $6.9 billion in 2009 to almost $32 billion by 2018. This market spans many specialties, the biggest of which is therapies for degenerative and traumatic orthopedic and spine applications. Other disorders that will benefit from cell therapies include cardiac and vascular disease, a wide range of neurological disorders, diabetes, inflammatory diseases, and dental decay injury. Key factors expected to influence the market for regenerative medicine are continued political actions, government funding, clinical trials results, industry investments, and an increasing awareness among both physicians and the general public of the accessibility of cell therapies for medical applications.

The MedMarket Diligence Report, "Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018", examines the status of technologies, applications and markets for tissue engineering, cell therapy and tissue/cell transplantation.

See a recent post in advanced medical technologies and the February 2010 MedMarket Diligence report #S520.

New RSS Feed on Medtech Financings

pjd@mediligence.com (Patrick Driscoll) — Mon, 1 Feb 2010 09:59:08 -0800

Given the significance of its impact on the creation and development of new medical technologies as well as the startup of new medtech companies, MedMarket Diligence is adding its Medtech Financing RSS feed to the list of feeds it currently provides on medical technologies.

The new Medtech Financing RSS feed is at http://mediligence.com/rss/medtech-financing.xml.

The MedMarket Diligence RSS Feeds now include:

New Medical Technologies
Medtech Developments
Surgical Technologies
Interventional Cardiology
Reports
Medtech Finanancing

Technologies and worldwide markets in wound management

pjd@mediligence.com (Patrick Driscoll) — Thu, 14 Jan 2010 15:07:07 -0800

(Coverage of wound management technologies and markets worldwide in MedMarket Diligence  report #S247.)

Wound management as a clinical practice and science is about as well established as any in the field of medicine.  Given the number of patients annually with need of wound management, the market for these products is also very well established. However, any suggestion that these facts reflect a stagnant market is unfounded, as the need for improving wound closure and healing to reduce the overall time and cost is significant, creating big opportunities for continued medical technology development.

The science of wound management has been evolving, driven by new technologies that capture and integrate new understanding of the wound healing process. The result is that there is a panoply of alternative wound management products on the market and under development, with widely variable rates of market growth:

Source: MedMarket Diligence, LLC, Report #S247: "Worldwide Wound Management: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World, 2008-2017."

The range of technologies encompass multiple dressing types (films, hydrocolloids, foams, etc.) and the more emerging technologies of tissue engineering, growth factors and physical therapies.  Moreover, physical therapies, which represent some of the most active wound management technologies, include a diversity of technologies:  negative pressure devices, positive pressure devices, mechanically assisted wound closure, and other physical therapies (hydrotherapy, electrical stimulation, electromagnetic stimulation, ultraviolet therapy, hyperbaric oxygen therapy, ultrasound devices, and laser devices).

Current clinical applications in tissue engineering and cell therapy

pjd@mediligence.com (Patrick Driscoll) — Thu, 7 Jan 2010 12:47:38 -0800

Approaches to the use of tissue engineering and cell therapies are varied, but all capitalize on the inherent healing abilities that can be leveraged in normal cell and tissue repair and development. The clinical applications have also proliferated, not simply in terms of the potential patient caseload, but in the actual patient populations for which treatments are in trial if not in current, approved use.

When we previously provided a global analysis of tissue engineering and cell therapy markets (2005), our perspective on the near- and mid-term market prospects was to mitigate the wildly optimistic views that pervaded forecasts.

The current list of clinical applications includes specific treatments in the categories of Coronary Heart Disease, Neurological, Orthopedic,
Urological, Skin/Integumentary, Dental, Organ Transplantation, Ophthalmology, Gastrointestinal, Ear, Nose and Throat/Respiratory/Cardiopulmonary, and Cancer.

See specific clinical applications in the recent post in advanced medical technologies and the January 2010 MedMarket Diligence report #S520.

Anti-restenosis in treatment of coronary artery disease

pjd@mediligence.com (Patrick Driscoll) — Tue, 5 Jan 2010 12:13:02 -0800

Anti-restenosis is a central focus of medtech manufacturers vying for caseload in the interventional cardiology market. This is driving the competing efforts of drug-eluting, bare metal, and bioabsorbable stents, as well as drug-eluting balloons and other technologies. The "advanced medical technologies" blog highlights the efforts of manufacturers in this field, with data drawn from the MedMarket Diligence report #C245, "Worldwide Coronary Stents Market."

Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017. Report #C245

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: stent, drug-eluting, interventional cardiology, restenosis

Negative/positive pressure, mechanically assisted wound closure, other wound therapies

pjd@mediligence.com (Patrick Driscoll) — Tue, 5 Jan 2010 12:04:44 -0800

Physical modalities have been used in the attempt to encourage wound healing for centuries. These include negative pressure devices, positive pressure devices, mechanically assisted wound closure and other physical systems.

The advanced medical technologies blog, drawing from the MedMarket Diligence Worldwide Wound Management Market report #S247, highlights the technologies in physical wound healing.

Coronary stents in the context of CAD treatment alternatives

pjd@mediligence.com (Patrick Driscoll) — Mon, 16 Nov 2009 12:19:16 -0800

Given the press on specific medical technologies, particularly those with large associated markets, the overall competitive landscape can sometimes be distorted. This is certainly the case with coronary artery stents. The emergence of a multi-billion dollar market for these stents over the past decade, and the emergence of the drug-eluting stent option, first by Johnson & Johnson, then Boston Scientific, seems to suggest that coronary artery disease (CAD) is now and forever shall be dominated by drug-eluting stents. However, despite this apparent trend (since past is not always prologue), their are multiple clinical options available, and emerging, for the treatment of coronary artery disease. In recent posts on the advanced medical technologies blog, we note the treatment options and even the treatment "map" that represents the current and future alternatives for CAD.

To hammer the point, It is worth noting that one radical alternative to stenting and bypass for CAD -- the dyslipidemia treatment by Esperion Therapeutics' ETC-1002, has advanced to Phase I trials this week.

Coronary artery disease treatment options

pjd@mediligence.com (Patrick Driscoll) — Thu, 5 Nov 2009 22:27:09 -0800

Because of the invasive nature of cardiac surgery, medical therapy will always be the preferred treatment protocol favored by many clinicians. To that end, device and pharmaceutical manufacturers continue to explore methods of treating atherosclerosis that will render surgery unnecessary.

For instance, researchers at the Medical University of Graz in Austria announced in February 2009 (Journal of Lipid Research, 50:312-326) progress related to their study of a synthetic atherosclerosis drug that can reduce the build-up of plaque without producing the side effect of fatty liver disease, which can lead to other disorders such as diabetes. However, in some instances, more aggressive therapy is required and for those patients, there is a host of therapy choices available -- all of which can prove to be competitive with stenting technology.

The range and diversity of alternatives for treatment of acute coronary artery disease are striking:

angioplasty with or without stenting
atherectomy
coronary artery bypass grafting

open CABG
off-pump CABG
MIDCAB (minimally invasive direct coronary artery bypass)
RACAB (robotic assisted coronary artery bypass)
other CABG

genetic therapies
transmyocardial laser revascularization
HDL therapy
drug-eluting balloons
nanoparticles and other agents

While the caseload distributed across these alternatives is concentrated in angioplasty (with stenting) and coronary artery bypass grafting, the acute nature of coronary artery disease, the size of the caseload and the continued pressure on clinicians to reduce the associated trauma of treatment give incentive to developers seeking to produce better outcomes.

The MedMarket Diligence report #C245 is described at http://www.mediligence.com/rpt/rpt-c245.htm and details the worldwide market for the use of alternative stent devices in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.

The report is described at this link. The report may be ordered for immediate download online.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA

Venture Capital Firms, Incubators with Medical Technology Portfolios

patrick@mediligence.com — Wed, 28 Oct 2009 13:19:43 -0700

Occasionally, I update my list of venture capital groups, selected incubators and other sources of funding or other support in healthcare, especially for medical device and other life science companies. Most though not all of the links provided are directly to each company's portfolio page. (With so many links in this list, inevitably there are a handful of the portfolio pages that are in the process of being updated or temporarily offline; check back later.)

Medical technology market reports:

Worldwide Wound Management, Report #S247
Worldwide Coronary Stents, Report #C245
Worldwide Surigical Sealants, Glues, Wound Closure, Report #S175
Worldwide Ablation Technologies, Report #A125

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: venture capital, medtech

Growth of coronary stent market in Japan, China (MedMarket Diligence report)

pjd@mediligence.com (Patrick Driscoll) — Sun, 25 Oct 2009 15:34:36 -0700

The market for coronary stents in the Asia/Pacific region is, unsurprisingly, dominated by Japan and China. However, these two markets demonstrate different rates of new technology adoption, resulting in a market segmentation that differs between them and the rest of the world.

The advanced medical technologies blog highlights the relative growth of the coronary stent market by segment in Asia/Pacific.

The MedMarket Diligence report #C245 is described at http://www.mediligence.com/rpt/rpt-c245.htm and details the worldwide market for the use of alternative stent devices in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.

The report provides full year (actual) 2008 market size and share data, with forecast market data to 2017, for the U.S., Europe, Asia/Pacific and Rest of World.

The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The report is described at this link. The report may be ordered for immediate download online.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes dedicated Reports on medical technology markets and offers the Medtech Startups Database on hundreds of newly founded medtech companies.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA

Wound management rapidly adopting advanced technologies, according to new MedMarket Diligence report

patrick@mediligence.com — Mon, 19 Oct 2009 11:18:32 -0700

Traditional wound management is comprised of technologies that do little to accelerate wound healing. Given chronic wound costs, advanced technologies are now being rapidly adopted to change this, according to a new MedMarket Diligence report.

See the recent PRLog press release here.

The MedMarket Diligence 2009 report on the Worldwide Wound Management Market selects, for discussion and analysis, those products that may be categorized as representing advanced wound management approaches and technologies, and the companies involved in this field. The report provides information of the causes and expected route of healing for wounds, to provide a clear understanding of the numbers of wounds that need to be treated characterized by wound type, and describe the role of advanced wound care products and services in overall wound management. The report describes the focus and strategies of key companies and outline their total sales in the advanced wound management sector.

MedMarket Diligence's September 2009 report, "Worldwide Wound Management, 2008-2017: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World", assesses the current and forecast market, and market opportunities, for established and emerging products and technologies in wound management. The report is described, with complete table of contents and list of exhibits, at this link.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: wound care, wound management, dressings, bandages, negative pressure, non-adherent, decubitus ulcer, stasis ulcer.

Developments in surgical and interventional technologies

patrick@mediligence.com — Fri, 16 Oct 2009 10:19:06 -0700

Surgical technologies, historically represented by devices like scalpels, retractors and sutures, have now come to be represented by devices, biomaterials, capital equipment and every manner of technology in between. Surgery has also be confronted head-on by competition from interventional technologies, which have proven to provide outcomes competitive with surgery, but with dramatically less trauma.

The advanced medical technologies blog highlights developments and markets in surgical and interventional technologies.

See recent surgical and interventional technology reports from MedMarket Diligence:

Worldwide Wound Management Market, 2008-2017. Report #S247
Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017. Report #C245
Worldwide Surgical Sealants, Glues, Wound Closure and Anti-adhesion Markets, 2009-2013. Report #S175
Ablation Technologies Worldwide Market, 2008-2017. Report #A125

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgery, surgical, interventional, wound management, dressings, bandages, negative pressure, non-adherent, decubitus ulcer, stasis ulcer, surgical sealant, surgical glue, stent.

Neurological applications of surgical sealants, closure and hemostasis

patrick@mediligence.com — Mon, 5 Oct 2009 16:34:50 -0700

One of the key areas of interest for development of products in surgical sealing, closure and hemostasis is in neural tissue surgery, encompassing chronic stroke, spinal cord trauma, neurovascular defects, and brain tumor treatments. In the U.S. alone, there were some 5.6 million patients in this category in 2008 who could benefit from these products.

The "advanced medical technologies" blog reviews the potential applications and prevalence of caseload for neurological use of surgical sealants, closure and hemostasis.

Data and analysis was drawn from Report #S175, "Worldwide Market for Sealants, Glues and Wound Closure, 2009-2013."

MedMarket Diligence's global analysis on the market and opportunities for products in surgical securement (surgical sealants, glues and other wound closure, hemostasis, and anti-adhesion) is described, with complete table of contents and list of exhibits at this link.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion, hemostasis>

Trends in the management of surgical wounds

patrick@mediligence.com — Mon, 5 Oct 2009 12:15:06 -0700

Surgical wounds account for the vast majority of skin injuries. We estimate that there are over 100 million surgical incisions a year, which require some wound management treatment. Approximately 80% of these wounds use some form of closure product (sutures, staples, and tapes). Many employ hemostasis products, and use fabric bandages and surgical dressings.

Surgical wounds are projected to increase in number at an annual rate of 3.1%, but overall the severity and size of surgical wounds will continue to decrease over the next ten years as a result of the continuing trend toward minimally invasive surgery.

Surgical procedures generate a preponderance of acute wounds with uneventful healing and a lower number of chronic wounds, such as those generated by wound dehiscence or post-operative infection. Surgical wounds are most often closed by primary intention, using products such as sutures, staples, or glues, where the two sides across the incision line are brought close and mechanically held together. Surgical wounds that involve substantial tissue loss or may be infected are allowed to heal by secondary intention where the wound is left open under dressings and allowed to fill by granulation and close by epithelialization. Some surgical wounds may be closed through delayed primary intention where they are left open until such time as it is felt it is safe to suture or glue the wound closed.

A significant feature of all wounds is the likelihood of pathological infection occurring. Surgical wounds are no exception, and average levels of infection of surgical wounds are 7%-10% dependent on the procedure. These infections can be prevented by appropriate cleanliness, surgical discipline and skill, wound care therapy, and antibiotic prophylaxis. Infections usually lead to more extensive wound care time, the use of more expensive products and drugs, significantly increased therapist time, and increased morbidity and rehabilitation time. A large number of wounds will also be sutured to accelerate closure, and a proportion of these will undergo dehiscence and require aftercare for healing to occur.

Technologies and recent medical technology startups (September/August)

patrick@mediligence.com — Wed, 30 Sep 2009 17:40:01 -0700

Below are the technologies under development at recently founded medical technology companies, detailed in the Medtech Startups Database from MedMarket Diligence:

September

Medical devices to enable deployment of vascular implants
Tibial prosthesis
Tools for performing less invasive orthopedic joint procedures.
Technologies in in vitro fertilization (IVF)
Medical device company developing antimicrobial materials for treatment of infections disease.
Minimally invasive device technologies.
Extracellular matrices for soft tissue regeneration.
Portable home hemodialysis.
Intravenously placed electrodes to stimulate the diaphragm as replacement for traditional mechanical ventilation.
Photonic based surgical technologies platform.

August

Finger-mounted ultrasound probe.
Diagnostic and medical device technologies.
Device to increase cerebral blood flow in stroke, Alzheimer's and other conditions.
Device for the treatment of bowel incontinence. (A Shalon Ventures portfolio company.)
Endoscopic treatment for gastric reflux.RF ablation technology for aesthetic applications.
Stealth company developing non-spine orthopedic technology

For more information on medical technology startups, see the Medtech Startups Database.

Recent reports from MedMarket Diligence:

Sales growth globally for surgical sealants, glues and hemostats driven by new products, clinical acceptance

patrick@mediligence.com — Tue, 2 Jun 2009 06:55:42 -0700

Between 2008 and 2013, significant growth will be seen in the aggregate sales of products in securement (sealants, glues, sutures/staples, hemostasis, anti-adhesion), but will be driven specifically by growth in the markets for fibrin and other sealants and high-strength glues. These products have long represented high potential for application to surgical and other wounds, but steady development and improvement of products, combined with the adoption by clinicians increasingly comfortable in applying them, are resulting in strong actual and continued sales growth.

Source: MedMarket Diligence report #S175, "Worldwide Surgical Sealants, Glues and Wound Closure, 2009-2013."

These products are demonstrating market growth and potential by penetrating existing caseload and expanding the total market for securement and closure of soft tissue.

MedMarket Diligence has published its global analysis on the market and opportunities for products in surgical securement (surgical sealants, glues, other wound closure, hemostasis, and anti-adhesion). See report #S175.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Drug-Eluting Stents' Dominance of Coronary Stent Market is Transient

pjd@mediligence.com (Patrick Driscoll) — Wed, 9 Sep 2009 13:51:08 -0700

The global market for coronary stents is owned largely by drug-eluting stents (DES), but the size of the patient pool, the drive for lowered cost, ever-increased efficacy and less trauma are spawning the development of multiple new technologies in coronary stents and competitive anti-restenosis technologies. The global market, products, companies, trends and opportunities are the subject of the 2009 report, "Worldwide Coronary Stents 2009," from MedMarket Diligence.

Currently, drug-eluting stents (DES) command 60% of typical markets for coronary stents and, in some markets like China, the share is much higher. Growth in the market for DES, at over 7%, is more than twice what it is for bare metal stents, since DES have demonstrated, through anti-restenosis, the ability to considerably reduced the need for repeat revascularization. The market for coronary stents will therefore continue to grow, penetrating deeper into bare metal stent markets and furthering the erosion of demand for the more invasive surgical alternative, coronary artery bypass grafting.

"The number of active companies and the size and growth of the market for coronary stents speaks to the intensity of development," says Patrick Driscoll of MedMarket Diligence, publisher of the report, 'Worldwide Coronary Stents Market, 2009'. At least 75 companies are active in this arena, with current products on the market or at various stages of development. Few avenues are being overlook in development, from stent material types, stent surface technology, drug-coating alternatives, drug-coating processes and others.

Development of stent alternatives also includes bioabsorbable stents, which may be the likely successor to drug-eluting stents if they achieve the goal of providing revascularization with markedly better long-term clinical outcomes. Bioabsorbales under development may well enter some markets as soon as two years from now.

Moreover, the premise of drug-eluting stents is being challenged through alternatives like drug-eluting balloon angioplasty and other device and non-device alternatives.

The MedMarket Diligence report #C245 is described at http://www.mediligence.com/rpt/rpt-c245.htm and details the worldwide market for the use of alternative stent devices in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.

The report provides full year (actual) 2008 market size and share data, with forecast market data to 2017, for the U.S., Europe, Asia/Pacific and Rest of World.

The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The report is described at this link. The report may be ordered for immediate download online.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes dedicated Reports on medical technology markets and offers the Medtech Startups Database on hundreds of newly founded medtech companies.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

High medical cost the target of chronic wound treatments

patrick@mediligence.com — Sat, 5 Sep 2009 10:36:16 -0700

Chronic wounds, which persist as a result of poor local circulation, localized pressure and other causes, alone or in combination, are responsible for high and growing costs in healthcare.

A recent post on the "advanced medical technologies" blog notes the impact of cost on the focus of medical technology development effortss.

MedMarket Diligence's pending (September 2009) report, "Worldwide Wound Management, 2008-2017: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World", assesses the current and forecast market, and market opportunities, for established and emerging products and technologies in wound management.

The report is described, with preliminary table of contents and list of exhibits, at this link.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: wound care, wound management, dressings, bandages, negative pressure, non-adherent, decubitus ulcer, stasis ulcer>

Coronary Stent Market Remains Highly Competitive, According to Global Market Report from MedMarket Diligence

pjd@mediligence.com (Patrick Driscoll) — Mon, 31 Aug 2009 16:19:56 -0700

The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence.

Since the advent of coronary stents, followed by the emergence of drug eluting stents, the field of stents in the treatment of coronary artery disease has been characterized by aggressive development of new technologies, from minor changes in strut design and drug-coating processes to more radical thinking of the kind that lead from bare metal stents to drug-eluting stents. The coronary stent market is currently in a phase in which the clinical and market success of drug-eluting stents introduced six years ago has stimulated innovation toward emergence of new drug-eluting stent types from many competitors. While the less invasiveness of coronary stents (delivered percutaneously) and outcomes of drug-eluting stents that are nearly comparable to coronary bypass are enabling coronary stents to expand the absolute market of coronary stents by capturing caseload from CABG, the market once dominated by Johnson & Johnson's Cordis division is now becoming progressively fragmented with new competitors. The market is now facing new challenges with the pending emergence of bioabsorbable stents, drug-eluting balloons and other competitive alternatives to the established stent market.

The global market for coronary stents, examining the products, technologies, companies and worldwide markets for bare metal, drug-eluting and other coronary stents, is the subject of MedMarket Diligence's report #C245, "Worldwide Coronary Stents 2008-2017" (published May 2009). See link.

"The nature of coronary artery disease, as a major source of morbidity and mortality worldwide, and the support (including especially reimbursement) that treatments receive in the healthcare arena, is a major impetus for technology development," says Patrick Driscoll of MedMarket Diligence. According to Driscoll, there are no fewer than 75 active companies developing and marketing coronary stents and competitive technologies, and the market is likely to become even more consolidated unless new, innovative anti-restenosis technologies are introduced that demonstrate profound clinical advantages over existing options.

The market is facing the emergence, in particular, of bioabsorbable stents, which have demonstrated their potential to provide the necessary anti-restenotic benefit following percutaneous intervention (e.g., angioplasty), then "simply" dissolve and be absorbed at six months or later. Such a device has the potential to eliminated longer term biocompatibility and otherwise inflammatory risk associated with permanently implanted stents. Bioabsorbable stents, too, may be bare or, more likely, containing drug coatings.

The MedMarket Diligence report details the worldwide market for the use of alternative stent devices (cardiac stents or heart stents) in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.

The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The report is described at this link. The report may be ordered for immediate download online.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes dedicated Reports on medical technology markets and offers the Medtech Startups Database on hundreds of newly founded medtech companies.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

An established, but also emerging wound care market

patrick@mediligence.com — Sat, 22 Aug 2009 15:03:12 -0700

One of the most well established medical technology markets, for a relatively mundane clinical demand -- the care of wounds -- also mirrors the diversity of technology development across the full range of medical science.

The advanced medical technologies blog highlights the nature of this unusual, well-established but innovation-driven, markets.

MedMarket Diligence's pending (September 2009) report, "Worldwide Wound Management, 2008-2017: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World", assesses the current and forecast market, and market opportunities, for established and emerging products and technologies in wound management.

The report is described, with preliminary table of contents and list of exhibits, at this link.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: wound care, wound management, dressings, bandages, negative pressure, non-adherent, decubitus ulcer, stasis ulcer>

Approved neurosurgery indications for high-strength surgical glues in Europe

patrick@mediligence.com — Wed, 19 Aug 2009 10:31:33 -0700

High-strength glue products were approved for topical closure applications in the United States in the late 1990s. Outside the United States, high-strength glues and adhesives have been approved in some countries for a number of years and have built up a track record of use in internal surgery. With time, high-strength glues will come to be used in a wider range of procedures and enable new procedures to be performed more economically with better outcomes and reduced morbidity and mortality.

We have reviewed applications and indications of commercial products and include a list of approved and indicated neurosurgery procedures in the European Union, as it illustrates the growing potential for these high-strength glues once they gain universal approval and adoption within the surgical community worldwide.

(See the complete list of procedures in Europe for high strength glues, encompassing the specific procedures in cardiac surgery, digestive tract endoscopy, general surgery, gynecological surgery, urological surgery, interventional radiology and vascular neuroradiology, pediatric surgery, and ENT surgery in Report #S175.)

MedMarket Diligence's global analysis on the market and opportunities for products in surgical securement (surgical sealants, glues and other wound closure, hemostasis, and anti-adhesion) is described, with complete table of contents and list of exhibits at this link.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion, hemostasis>

Adoption of drug-eluting versus bare metal stents varies geographically

pjd@mediligence.com (Patrick Driscoll) — Thu, 13 Aug 2009 14:07:56 -0700

Coronary stents have demonstrated a uniquely different pattern of adoption in different parts of the world. The typical differences between the U.S., Europe and other geographies in terms of relative share of the market, do not apply for coronary stents. In particular is the case of China.

The advanced medical technologies blog highlights the geographic growth in the use and market for drug-eluting stents versus bare metal stents, with variable opportunity in major geographic areas.

Global market size and growth in coronary stents are the subject of the MedMarket Diligence report #C245, "Worldwide Coronary Stents Market, 2008-2017" (published May 2009). The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Alternative drug/coating developments for drug-eluting stents

pjd@mediligence.com (Patrick Driscoll) — Sun, 9 Aug 2009 09:09:11 -0700

Drug-eluting stents have faced questions, but continue to grow in clinical use and market expansion. The advanced medical technologies highlights drugs/coatings in development for drug-eluting stents.

Alternatives in wound closure technologies and clinical practice

patrick@mediligence.com — Wed, 5 Aug 2009 11:50:55 -0700

The field of wound closure, once dominated by sutures, now comprises a wide array of different options available to the clinician, who matches the wound type, location, patient status and other considerations to the specific wound closure technologies (or combinations of them) to optimize wound healing. The only list more numerous than the product types and applications is the list of active manufacturers developing and marketing these products.

The advanced medical technologies blog highlights the closure and securement applications, products and clinical options in wound healing.

MedMarket Diligence has published its global analysis on the market and opportunities for products in surgical securement (surgical sealants, glues, other wound closure, hemostasis, and anti-adhesion). See report #S175).

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion, hemostasis>

Growth in surgical procedures and new techniques driving markets for surgical closure and securement

patrick@mediligence.com — Tue, 28 Jul 2009 08:19:22 -0700

Major surgical procedures, as in cardiovascular and spine surgery, continue to evolve to reduce invasiveness, minimize complications and improve clinical outcomes. Caseloads remain persistently high in many surgical applications by virtue of the acute nature of the conditions, the clinical benefits derived from surgery, and the demographics of the aging population.

The advanced medical technologies blog explores this underlying set of drivers for the use of advanced surgical closure and securement products, including surgical sealants, glues, hemostasis and other wound management products. These products are continuing to penetrate traditional products for management of surgical and traumatic wounds.

MedMarket Diligence has published its global analysis on the market and opportunities for products in surgical securement (surgical sealants, glues, other wound closure, hemostasis, and anti-adhesion). See report #S175).

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Drug-eluting stent market, geographic growth

pjd@mediligence.com (Patrick Driscoll) — Sun, 26 Jul 2009 09:37:52 -0700

The market for drug-eluting stents has shown strong growth worldwide, despite the temporary blip resulting from clinical data suggesting thrombosis risk and comparative effectiveness against bare metal stents.

The advanced medical technologies blog highlights the geographic growth in the use and market for drug-eluting stents, with variable opportunity in major geographic areas.

Global market size and growth in coronary stents are the subject of the MedMarket Diligence report #C245, "Worldwide Coronary Stents Market, 2008-2017" (published May 2009). The report may be purchased for immediate download online or may be ordered via order form.

(Twitter users search .twitter.comfor MedMarket coupon options.)

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

High-strength surgical glues: From the outside looking in

patrick@mediligence.com — Wed, 8 Jul 2009 12:02:21 -0700

Their use in topical applications is common and growing, despite the fact that high-strength glues are not as strong as sutures. Their ease of use, ability to reduce or eliminate scarring and, probably most importantly, their effective marketing by manufacturers are all factors leading to their strong historic, and forecast, market growth. However, challenges remain for the application of high-strength glues for internal applications, given the need for better adhesion and the problem of toxicity of existing glues, which are predominantly cyanoacrylate-based.

The advanced medical technologies blog highlights high strength glues and their opportunities and challenges, with data drawn from the MedMarket Diligence report #S175, "Worldwide Market for Surgical Sealants, Glues and Wound Closure, 2009-2013."

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Coronary Stents: Emerging New Stent Alternatives

pjd@mediligence.com (Patrick Driscoll) — Wed, 8 Jul 2009 08:55:49 -0700

Bare metal stents and drug-eluting stents (DES) are well established. Industry participants are also well along toward developing bioabsorbable stents. But there remain a number of unique stent technologies in advanced stages of development, one or more of which have excellent potential to impact existing markets.

Pericardium covered
Radioactive stents
Biomimetic coatings
Hydrophilic coatings
Titanium-nitride-oxygen coatings
Genetically-engineered bioactive coating
Endothelial cell-stimulating coatings
Synthetic graft stent alternative
Nano-polymer coatings
Stent with embolic protection

While drug-eluting stents have gained solid and growing shares of the worldwide stent market, interventional cardiologists and healthcare systems have demonstrated considerable propensity to shift toward or away from different stent alternatives based on available data --- even incomplete data, which was clearly the case with late-stage thrombosis putting a temporary pinch on DES sales (see also recent data on Xtent's Custom NX that may just pull Xtent back from the brink of shutting down). Aggressive innovators in stent technologies may be rewarded with substantial caseload if their designs can demonstrate even nominal improvements over available stents, a point embraced as readily by the market leaders as by one-device companies.

Stent technologies and markets globally are the subject of the MedMarket Diligence report #C245, "Worldwide Coronary Stents Market, 2008-2017" (published May 2009). The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Stents: The ideal treatment for coronary artery disease?

pjd@mediligence.com (Patrick Driscoll) — Sat, 4 Jul 2009 12:28:05 -0700

Stents (drug-eluting/drug-coated, bare metal and bioabsorbable) may well represent the ideal treatment for coronary artery disease. Although options available to clinicians continue to emerge, and existing ones evolve, the performance (clinically and economically) of stents compared to invasive surgery (or even minimally invasive coronary artery bypass) is driving their success in global markets. The advanced medical technologies blog, drawing on the MedMarket Diligence global stent market report #C245, details the major stent (and other anti-restenosis) technology on the market and in development.

MedMarket Diligence has recently published (May 2009) report #C245, "Worldwide Coronary Stents Market, 2008-2017". The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Ablation technologies proliferate from their many clinical benefits

pjd@mediligence.com (Patrick Driscoll) — Mon, 29 Jun 2009 23:18:19 -0700

Ablation technologies are a surprisingly diverse group of treatments that have multiple clinical applications, but all have the potential to compete with each other, and most have significant existing markets, growth rates or both. The advanced medical technologies blog highlights the growth versus market size balance for the different ablation modalities.

Ablation technologies and their worldwide markets are subject of the market report from MedMarket Diligence report #A125.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: ablation, rf ablation, microwave, ultrasound, HIFU, laser, radiation, thermal ablation, electrosurgery.>

Novel coronary stent technologies

pjd@mediligence.com (Patrick Driscoll) — Mon, 29 Jun 2009 00:04:45 -0700

Competitors in the market for the treatment of coronary artery disease must face a litany of alternative technologies targeted at this patient caseload. In stents alone, there are multiple variants of coating types (or none) and materials on the market and in development. The advanced medical technologies blog, drawing on the MedMarket Diligence global stent market report #C245, highlights the range of these novel stent technologies .

Worldwide Market: Surgical Sealants and Glues (plus hemostasis, anti-adhesion)

patrick@mediligence.com — Sat, 27 Jun 2009 10:31:26 -0700

The advanced medical technologies blog highlights the global opportunities for products in surgical securement (surgical sealants, glues, other wound closure, hemostasis, and anti-adhesion), drawn from the worldwide surgical sealants, glues and wound closure report from MedMarket Diligence (report #S175).

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Coronary stent unit volume size, growth, by stent type

pjd@mediligence.com (Patrick Driscoll) — Sat, 27 Jun 2009 10:15:21 -0700

Size and growth rates in the unit volume sales of coronary stents vary by stent type: drug-eluting, bare metal and bioabsorbable stents. The advanced medical technologies blog, drawing on the MedMarket Diligence global stent market report #C245, graphically illustrates this.

Ablation technologies and their variable penetration of clinical applications

pjd@mediligence.com (Patrick Driscoll) — Tue, 16 Jun 2009 22:43:28 -0700

Applications of ablation technologies --- the use of energy-based and other modalities that cut, burn, freeze, vaporize or otherwise therapeutically destroy tissue -- have penetrated numerous clinical applications, but that penetration varies by modality and clinical application. The advanced medical technologies blog highlights the variable penetration of ablation technologies for treatment of cancer.

Ablation technologies and their worldwide markets are subject of the market report from MedMarket Diligence report #A125.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: ablation, rf ablation, microwave, ultrasound, HIFU, laser, cancer, oncology>

Treatment alternatives for coronary artery disease run the gamut of techniques, technologies

reports@mediligence.com — Thu, 4 Jun 2009 12:12:50 -0700

Treating atherosclerotic disease in coronary arteries has for some years been the target of multiple different clinical procedures and medical technologies. While much caseload is apportioned to either coronary artery bypass grafting or percutaneous coronary (cath lab) interventions, the variety goes beyond these two simple choices.

The advanced medical technologies blog details the range of options in place and under continued development as the technologies evolve and caseload shifts toward those providing optimal performance.

See the May 2009 report #C245, "Worldwide Coronary Stents Market, 2008-2017." The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Growth in patient caseload for surgical securement products

patrick@mediligence.com — Sat, 30 May 2009 10:13:48 -0700

Caseload continues to grow for the use of the broad category of products called "surgical securement", encompassing advanced products in surgical sealants, glues, hemostasis, and other wound closure and anti-adhesion products, according to a 2009 report by MedMarket Diligence, LLC.

"Worldwide, over 100 million surgical and traumatic wound types and applications are potential candidates for use of these products, and the breadth of these applications illustrate the great clinical utility of these products," says Patrick Driscoll of MedMarket Diligence. "These applications span cardiovascular, orthopedic and arthroscopic, digestive, urological, neurological, cosmetic, and general surgery, displacing many traditional wound closure products."

The market for surgical closure and securement has entered a phase in which major driving forces are the introduction of new procedures and techniques by the surgical profession, the development by the medical device industry of new wound closure devices and biomaterials, and the growing willingness of surgical specialists to use these devices in appropriate circumstances. There is now a continuum between simple closure using sutures and the use of specially designed devices and delivery systems with new bioresorbable securement materials either as supplements to conventional closure methodology or as stand-alone replacements.

Among all potential clinical applications, surgical securement products play critical roles in reducing mortality and complications for roughly 26 million surgical procedures and, in another 50 million surgical procedures, securement products provide distinct improvements in clinical outcomes. In another 40 million procedures, securement product reduce procedure time, provide cost savings or provide other benefits.

The MedMarket Diligence report #S175, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013," is a market and technology assessment and forecast of products in wound closure. The report details the current and emerging products, technologies and markets involved in wound closure and sealing using sutures and staples, tapes, hemostats, fibrin and sealant products, medical adhesives and products to prevent post-surgical adhesions. The report provides a worldwide current and annual forecast to 2013 of the markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade. The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan and Rest of World.

The report provides background data on the surgical, disease and traumatic wound patient populations targeted by current technologies and those under development, and the current clinical practices in the management of these patients, including the dynamics among the various clinical specialties or subspecialties vying for patient population and facilitating or limiting the growth of technologies.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

For more details on this report, including description, table of contents, list of exhibits and ordering information, see http://www.mediligence.com/rpt/rpt-s175.htm.

The report may be ordered online (for immediate download) from http://www.mediligence.com/store/page29.html or may be ordered via fax order form from http://www.mediligence.com/order_forms/s175_order.pdf.

About MedMarket Diligence
MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes dedicated Reports on medical technology markets and offers the Medtech Startups Database on hundreds of newly founded medtech companies.

# # #

MedMarket Diligence provides data and insight to the medical products, investment and other industries on advanced medical technologies through focused medical technology market and assessment Reports and the Medtech Startups Database.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

SYNTAX: Percutaneous Coronary Intervention (PCI) compared to Coronary Artery Bypass Grafting (CABG)

reports@mediligence.com — Sun, 24 May 2009 16:18:12 -0700

This is one of the largest clinical trials comparing PCI (with DES) with CABG. Results presented at TCT 2008 found no significant difference in treatment outcomes of patients who were stented compared with those who underwent coronary artery bypass grafting.

The advanced medical technologies blog reviews the SYNTAX trial (and notes the reviews of clinical trials detailed in the MedMarket Diligence Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." The report, described here, may be purchased online or via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Advanced securement products versus conventional products in non-USA Americas

patrick@mediligence.com — Thu, 21 May 2009 13:57:02 -0700

Taken together, the Americas represent some 60% of the global market, led by the United States with more than 50%. The main medical markets in Latin America are Brazil and Mexico, followed by Argentina.

The advanced medical technologies blog, drawing on MedMarket Diligence report #S175 on the Worldwide Market for Surgical Sealants, Glues and Wound Closure," highlights the markets for advanced surgical securement products (sealants, glues, hemostats, anti-adhesion) in the non-USA markets of the Americas.

The wealthier, private-insurance-dominated healthcare market in the USA drives a heavier share of securement product sales in the advanced sector (sealants, glues, hemostats, anti-adhesion) compared to the large Latin American markets of Brazil, Argentina and Mexico, where conventional securement products (sutures, staples, tapes) predominate. However, growth remains strongest for advanced securement products -- in all geographic markets.

Securement products worldwide are described in the MedMarket Diligence report #S175.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Dermal repair disorders, prevalence and applications for securement products

patrick@mediligence.com — Wed, 20 May 2009 21:10:42 -0700

Skin securement has always been an essential final step in surgical procedures. Historically, the skin surface was sutured; in recent years a number of advances have been made, including new tapes, sutures, staples, hemostats, and glues. High strength glues, in particular, find some of their biggest potential in dermal applications, given the problems of, for example, cyanoacrylate toxicity for internal applications.

The advanced medical technologies blog, drawing on MedMarket Diligence report #S175 on the Worldwide Market for Surgical Sealants, Glues and Wound Closure," illustrates the potential for surgical securement products for their application in treatment of venous ulcers, pressure ulcers, and burns, as well as for their significant volume of usage in plastic surgery.

Securement products worldwide are described in the MedMarket Diligence report #S175.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Taking the lead in the coronary stent market: U.S.? Europe? China?

reports@mediligence.com — Tue, 19 May 2009 20:53:18 -0700

For many medical technology markets, the dynamics of technology development are usually such that innovation arises in western economies (especially U.S. and Europe) and migrates to Asia/Pacific and the rest of the world.

But the dynamic is different in the market for coronary stents. And it has much less to do with technology migration than market size.

The advanced medical technologies blog, drawing on the May 2009 report #C245, "Worldwide Coronary Stents Market, 2008-2017," explores the geographic impact of different coronary stent types.

Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." The report, described here, may be purchased for immediate download (and with limited time discount) online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Adoption of surgical securement products by clinical category and key determinants

patrick@mediligence.com — Tue, 19 May 2009 17:07:11 -0700

The potential for products in the surgical securement (sealants, glues, sutures/staples, hemostats, anti-adhesion) is driven by clinical category and the impact of the particular products, in each specialty, on a hierarchy of determinants, from the "important and enabling" to the "aesthetic and perceived benefits". This results in a variable distribution by clinical category (see blog entry for category definitions) in the potential of each.

The development, adoption, use and markets for securement products worldwide are described in the MedMarket Diligence report #S175.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Despite multiple therapeutic alternatives, opportunities remain strong for coronary stent manufacturers

reports@mediligence.com — Fri, 15 May 2009 14:20:49 -0700

Because the ultimate therapy for the treatment of coronary artery disease has not yet been found, many opportunities still exist for effective therapies to combat atherosclerosis. So far, coronary stents hold the most promise for effectively treating an aging population with an increasing incidence of coronary artery disease.

The "advanced medical technologies" blog sources the MedMarket Diligence report #C245 on the worldwide coronary stents market in highlighting the opportunities for stents in the treatment of coronary artery disease -- despite multiple therapeutic alternatives.

Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." The report, described here, may be purchased for immediate download (and with limited time discount) online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Coronary Stents Market Worldwide Holds Big Incentive for Growth, Opportunity in Novel Technologies, According to New MedMarket Diligence Report

reports@mediligence.com — Mon, 4 May 2009 09:15:59 -0700

The market for coronary stents is, in many ways, still emerging. While coronary stents have been on the commercial market in one form or another for several years, the technologies and materials used to create the devices are improving every day. In addition, innovative technology is bringing new classes of devices (e.g., fully degradable stents) to market, technologies that grow the market and even expand stent therapy to new patient populations in some cases.

Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." The report, described here, may be purchased for immediate download (and with limited time discount) online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Worldwide Coronary Stents Market

pjd@mediligence.com — Tue, 21 Apr 2009 12:57:54 -0700

The global market for drug-eluting, bare and bioresorbable stents for the treatment of coronary artery disease is in a "growth and proliferation" phase, as the market for these devices is growing steadily through application to growing patient caseload, and as the number of companies with approved products or products in development multiplies.
.
The advanced medical technologies blog highlights the three major sectors of coronary stents: drug-eluting, bare and bioresobable.

Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." The report, described here, may be advance purchased (with discount on paid orders) online or via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

New surgical techniques drive market opportunity in surgical sealants, glues market

patrick@mediligence.com — Wed, 15 Apr 2009 11:50:33 -0700

Changes in surgical practice, including the emergence of new surgical techniques, are creating and expanding the opportunities for surgical sealants, glues and wound closure.

The 2009 MedMarket Diligence report describes the expanding market opportunity for adjunctive surgical closure and securement products, gives an overview of the technical background for new products, describes existing competitors with products in relevant market segments, and offers five-year market growth estimates. The report covers sutures, staples, tapes, hemostats, surgical sealants, high-strength surgical glues, and adhesion prevention products.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Worldwide Market for Drug-Eluting, Bare, Bioresorbable and Other Coronary Stents, 2008-2017. New MedMarket Diligence Report

pjd@mediligence.com — Wed, 8 Apr 2009 14:12:03 -0700

Any treatment for coronary artery disease will of necessity consider the competitive threat of bare versus drug-eluting stents, angioplasty, atherectomy (waning but not gone), products for identification/treatment of vulnerable plaque, traditional coronary artery bypass, MIDCAB, OPCAB and other bypass variants (e.g. robotics), percutaneous bypass, atherosclerosis-reversing drugs and others.

From the manufacturer’s side, it is a complex competitive landscape. For example, once was that any angioplasty manufacturer could reasonably consider his/her competitors to be all other manufacturers of devices that produce catheter-based recanalization of the atherosclerotic lumen. Those days are gone, for woe the angioplasty manufacturer now who does not also consider atherectomy, transmyocardial laser revascularization, bare metal stents, drug-eluting stents, traditional/open, MIDCAB (and similar) or and even percutaneous coronary artery bypass graft, let alone the classes of drugs and other non-device approaches to produce non-surgical reversal of atherosclerosis
.
MedMarket Diligence, drawing on its coverage of coronary stents through the previously published MedMarkets publication and leveraging its expertise in assessing advanced medical technologies markets, is publishing its 2009 report, "Worldwide Market for Drug-Eluting, Bare, Bioresorbable and Other Coronary Stents, 2008-2017."

Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." The report, described here, may be advance purchased (with discount on paid orders) online or via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Worldwide Surgical Sealants, Glues, Wound Closure, Anti-Adhesion Markets, 2009-2013. MedMarket Diligence Report

patrick@mediligence.com — Sun, 5 Apr 2009 18:22:35 -0700

The 2009 MedMarket Diligence report describes the expanding market opportunity for adjunctive surgical closure and securement products, gives an overview of the technical background for new products, describes existing competitors with products in relevant market segments, and offers five-year market growth estimates. The report covers sutures, staples, tapes, hemostats, surgical sealants, high-strength surgical glues, and adhesion prevention products.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Ablation technologies in cardiology, oncology, general surgery, gynecology, elective surgery, and orthopedics. Worldwide market 2007-2017.

pjd@mediligence.com — Thu, 2 Apr 2009 14:38:52 -0700

Technologies for the therapeutic ablation of tissue include the use of radiofrequency, ultrasound, laser, microwave, thermal, hydromechanical, cryogenic, and electrical. These are routinely applied in cardiology, oncology, general surgery, gynecology, elective surgery, and orthopedics.

The MedMarket Diligence report #A125 details the worldwide market, to 2017 for each of these modalities, with segmentation by U.S., Canada, Brazil, Mexico, United Kingdom, Germany, Italy, France, Spain, BeNeLux, Japan, China, India, Australia and Rest of World.

The report is described in detail, with table of contents and list of exhibits, here. The report may be purchased via faxed order form or for immediate download online.

Tags: ablation, rf ablation, microwave, ultrasound, HIFU, laser>

Worldwide Coronary Stent Market Growth, Market Opportunities; April 2009 MedMarket Diligence Report

pjd@mediligence.com — Thu, 2 Apr 2009 10:09:29 -0700

The worldwide market for coronary stents, including drug-eluting, bare metal, bioabsorbable others, is reflecting all of the dynamics one would expect: high growth based on clinical success in providing an alternative to surgical (e.g., bypass) intervention, a proliferation of competitors (over 75 active companies) seeking market share, a diversification of available and developing technologies and challenges to the top players, J&J and Boston Scientific, who once reaped the early rewards of a monopoly-like status. The worldwide coronary stent market is detailed in the April 2009 report (#C245) by MedMarket Diligence.

The report may be ordered with an advance purchase discount (order form or online).

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Spine Fusion, Non-Fusion, Other Worldwide Spine Surgery Procedures, and Market Growth by Country (U.S., EU [Germany, UK, France, Italy]), Asia./Pacific, Rest of World

patrick@mediligence.com — Thu, 26 Mar 2009 08:31:44 -0700

Procedures and markets worldwide and by country are provided in the MedMarket Diligence Report #M510, "Spine Surgery: Products, Technologies, Markets & Opportunities, Worldwide, 2008-2017."

See the advanced medical technologies blog, which has numerous excerpts from the report, for a glimpse at this well-read industry report.

The MedMarket Diligence report on the "Worldwide Spine Surgery Market" is described here. and is available for purchase and immediate download here.

Tags: spine surgery, disc replacement, spine fusion, interbody fusion>

Drug-Eluting Balloons as Alternative to Combined Angioplasty/Stenting (MedMarket Diligence)

pjd@mediligence.com — Thu, 19 Mar 2009 11:05:46 -0700

As the huge worldwide market for coronary stents -- whether drug-coated, bare metal, bioabsorbable or other -- continues to expand and draw an increasing number of competitors, a handful of innovators are pursuing an alternative idea: drug-eluting balloons. The "advanced medical technologies" blog has a recent review of drug-eluting balloons, drawn from the forthcoming (April) publication of the MedMarket Diligence Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017."

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA>

Traditional Wound Closure (Sutures, Tapes, Staples) Undergoing Inexorable Shift Toward Use of Surgical Sealants and Glues, According to 2009 MedMarket Diligence Report

pjd@mediligence.com — Thu, 12 Mar 2009 14:37:24 -0700

The use of novel fibrin sealants, fibrin glues, medical adhesives and other products for wound closure has become nearly as routine as the use of traditional sutures, staples and tapes in wound closure. MedMarket Diligence's 2009 report on "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013" details the global market for wound closure and related products. The report is described here.

The report may be purchased online for immediate download.

Tags: medtech, surgical sealants, fibrin sealants, surgical glues, cyanoacrylates>

Products, technologies, companies and worldwide markets in hemostasis

pjd@mediligence.com — Sun, 8 Mar 2009 13:26:11 -0700

Distribution of wound closure, sealants, and other securement product sales in the Americas

pjd@mediligence.com — Fri, 6 Mar 2009 11:36:07 -0800

The distribution of wound closure products varies in the Americas. With varying degrees, surgical sealants are steadily penetrating wound closure markets that are, for the time being, still represented in the marjority by traditional sutures and staples.

The advanced medical technologies blog posts the distribution of wound closure products in the U.S., Brazil, Mexico, Argentina and other Latin American countries.

Drawn from Report #S175 by MedMarket Diligence.

Obesity costs rising, but spending on treatment has big positive impact on indirect costs

pjd@mediligence.com — Thu, 5 Mar 2009 13:25:26 -0800

Among all costs that are contributing to healthcare being expensive in the U.S., those associated with obesity must be near the top of the list. The advanced medical technologies blog highlights both why it is important for the U.S. to recognize this, but understand too that money spent on obesity treatment is well spent.

MedMarket Diligence's report on the "Worldwide Market for the Clinical Management of Obesity" is described, with full table of contents and list of exhibits, here.

The report can also be ordered online here.

Tags: obesity, bariatric,>

Medical technology opportunities driven by demand, enabling technologies and even economics

pjd@mediligence.com — Thu, 26 Feb 2009 07:38:35 -0800

Despite economic challenges (and in some cases because of them), opportunities are numerous in the medical technology arena. Enabling technologies and the persistent nature of demand for products in healthcare give rise to promising new products penetrating existing markets or even creating new ones.

A White Paper from MedMarket Diligence on high growth medical technologies details the technologies and opportunities. See link to register for free access.

New surgical techniques drive market opportunity in surgical sealants, glues market

pjd@mediligence.com — Sat, 21 Feb 2009 09:24:40 -0800

The active manufacturers in the market for sealants & glues technologies used in traumatic, surgical and other wound closure, (tapes, sutures and staples) as well as hemostats and anti-adhesion products are profiled in the December 2008 MedMarket Diligence report #S175, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013." The report is described here.

The report may be purchased online for immediate download.

Tags: medtech, surgical sealants, fibrin sealants, surgical glues, cyanoacrylates>

Medical technology platforms with high growth potential

pjd@mediligence.com — Wed, 18 Feb 2009 21:50:39 -0800

Review of top new medical technologies and/or platforms. Subject of MedMarket Diligence White Paper discussed in recent "advanced medical technologies" blog. Technologies include biotech alternatives to medical devices, drug-device hybrids, RFID, ablation, tissue engineering, bioresorbables, and others.

For a complete listing of MedMarket Diligence reports, see link. See also the Medtech Startups Database.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

>

New surgical techniques drive market opportunity in surgical sealants, glues market

pjd@mediligence.com — Wed, 18 Feb 2009 19:14:37 -0800

Growth in surgical techniques, many new, are increasing the size of the opportunity for surgical sealants, glues, hemostasis and other products. With surgeon experience growing in the new techniques, many of which are less invasive, the potential patient population for the procedures is increasing (e.g., spine surgery) as surgery is more completely penetrating the potential surgical caseload. The aging demographic simply adds to the momentum in this trend.

The "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013," is detailed in a new report from MedMarket Diligence. The report is described here.

Tags: medtech, surgical sealants, fibrin sealants, surgical glues, cyanoacrylates>

Trends and Opportunities in the Rapidly Growing Worldwide Ablation Technologies Market;

patrick@mediligence.com — Tue, 17 Feb 2009 09:35:03 -0800

The global market for medical devices is currently a $185 billion opportunity and at least 13% of this market involves products that provide the controlled application of energy to tissue. The segment is dominated by high technology products ranging from devices that can heat and cool tissue over a 600° C temperature range of -200° C to +400° C to those that can vibrate at fifty five thousand cycles per second to denature tissue. While a significant share of the energy-based therapies market is for elective procedures such as refractive eye surgery and cosmetic hair removal, treatments for chronic diseases make up the vast majority of the applications of these technologies.

Underlying the growth of this market will be changes in demographics. The baby boomer generation--those born between 1946 and 1964--represents about one-third of the population in economically-developed countries. Many of these ageing citizens have both the economic means and the demand for therapies that can extend their active lives and delay the visible signs of aging.

Pushing the growth of energy therapies beyond basic changes in demographics are the unique benefits that they offer. They are typically less invasive than traditional surgery and are generally employed without the need for an implant. The therapies can be precisely metered and can be repeated. Emerging energy modalities have the potential to grow at significant, double-digit rates over the next decade as delivery systems evolve.

The MedMarket Diligence report on the "Worldwide Ablation Technologies Market, 2008-2017" is described here. and is available for purchase and immediate download here.

>

Degenerative disc diseases, implications for spinal surgery technologies

patrick@mediligence.com — Mon, 16 Feb 2009 16:51:22 -0800

Degenerative disc disease are a major impetus for spine surgery. The advanced medical technologies blog, in an excerpt from the MedMarket Diligence report on Spine Surgery, reviews the clinical background for these conditions.

Product development timeline, clinical trends in hemostasis, medical/surgical sealants and glues, wound closure

pjd@mediligence.com — Tue, 3 Feb 2009 09:35:44 -0800

During the 19th century, surgeons began to experiment with materials designed to achieve hemostasis: gelatin, collagen, natural fabrics, and thrombin and fibrin materials. In the early 1980s today's commercial products began to appear. They were rapidly adopted in Japan where bleeding is an extremely emotive issue, and also in Europe where local regulatory requirements allowed a sequential roll-out of product introductions. In the United States, early FDA concerns associated with disease transmission led to delayed launch of products derived from human sources. These regulatory delays, plus the perceived high cost of products and surgeons' concerns regarding disease transmission risk, drove surgeons and hospitals to continue to look for alternative hemostats, sealants and glues. As a result, to this day there is a tendency for hospitals to continue to prepare autologous fibrin (from the patient’s own blood taken before surgery) and to use a number of inferior hemostasis products.

Topical high-strength glues were first used by the military and to achieve immediate repair of sports injuries during professional sports like ice hockey, boxing and American football and basketball. These products became the subject of collaborative efforts between innovative suppliers and major suture manufacturing and marketing companies, keen to evolve their product portfolios to include next-generation closure materials.

During the 1990s, many technology-based companies began to target the huge unmet closure and sealant market and extensive literature appeared, advising practitioners on specific methodology to create the ideal autologous fibrin sealant product and on applying these products to surgical indications. In addition, a number of specialist societies were established to support and advise on the process of preparing and using hospital-derived fibrin sealants.

There were also a growing number of companies developing medical devices and equipment specifically designed to allow the preparation of autologous fibrin sealant for surgical applications. All this effort led to a number of products being approved for use in the major surgical indications (see Exhibit 1-7, report #S175). In 2006, sealant products were used in over three million surgical procedures. This represents up to 5 million units of commercially available fibrin sealant products, and approximately four million units of autologous fibrin prepared by hospitals. The autologous fibrin material, prepared using commercial medical devices, was used in approximately 70,000 surgical operations worldwide and represents a new market that has developed over the last five years. Similarly, the use of high-strength glues for wound closure evolved since 1992 in Europe and since 1998 in the United States and Japan. High-strength adhesives were used on approximately 6 million cuts, grazes and minor incisions in 2006. This usage is growing rapidly driven by greater awareness and cost-effectiveness.

The above is an excerpt from "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013," the December 2008 report from MedMarket Diligence. The report is described in detail here.

Tags: medtech, hemostasis, surgical sealants, fibrin sealants, surgical glues, cyanoacrylates>

Growing Caseload, Range of Applications, Participating Companies and Worldwide Markets in Surgical Sealants, Glues, Hemostasis and Anti-Adhesion, According to MedMarket Diligence Report

pjd@mediligence.com — Wed, 28 Jan 2009 07:52:34 -0800

The steady rate of adoption by physicians using novel wound closure, hemostasis and anti-adhesion products, the growing caseload to which products are being applied, the proliferation of companies developing and introducing products and the expanding international markets for them are collectively responsible for the high growth in the market for these products.

The "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013," is detailed in a new report from MedMarket Diligence. The report is described here.

Tags: medtech, surgical sealants, fibrin sealants, surgical glues, cyanoacrylates>

Hemostasis in wound management

pjd@mediligence.com — Thu, 22 Jan 2009 07:42:55 -0800

Hemostat: A hemostat reacts in the presence of blood to establish the normal cascade of factors that arrest bleeding. These products can be added to a bleeding field during surgery to prevent further bleeding, and are mostly dependent on a full complement of normal factors in the patient's blood.

Hemostats have been used for over a hundred years to prevent bleeding in the surgical situation. Primarily these products were first introduced to prevent hematomas during surgery with the aim of preventing resultant infections. During the 1980s and 1990s, the popularity of hemostats increased rapidly as surgeons tried to avoid excessive use of blood transfusions for reasons of economy and the threat of disease transmission. Products were launched during this period by many of the large medical device manufacturers, such as Johnson & Johnson, which now sells Surgicel (an oxidized regenerated cellulose hemostat), Instat (a freeze-dried collagen product), Spongostan (a freeze-dried gelatin hemostat), and Thrombocoll (a freeze-dried thrombin powder). A myriad of products continue to be introduced to the market for hemostasis, targeting improved performance in a wider array of clinical applications.

As part of the detailed worldwide analysis of surgical sealants, glues and other wound closure and anti-adhesion products market, MedMarket Diligence assesses the products, technologies, competitors and worldwide markets for hemostasis.

Tags: medtech, hemostasis,surgical sealants, fibrin sealants, surgical glues, cyanoacrylates>

Surgical closure and securement products defined

pjd@mediligence.com — Tue, 20 Jan 2009 13:15:44 -0800

The market for securement products may be subdivided into the following product categories: sutures, staples and other mechanical closure devices; tapes; hemostats; fibrin and other sealants; high-strength medical adhesives; and post-surgical adhesion prevention. These are further defined in the advanced medical technologies blog.

MedMarket Diligence tracks wound closure, hemostasis and anti-adhesion technologies and forecasts this market in a forthcoming worldwide report, with insight into market introduction, growth, competition and business opportunity. The 2009 report details the markets worldwide, with detailed geographic segmentation, for surgical sealants, glues, hemostats, sutures, tapes, other wound closure technologies and products in the prevention of post-surgical adhesion.

The report is entitled, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013."

The report is detailed here and may be ordered by order form or via online order for immediate download.

Tags: medtech, surgical sealants, fibrin sealants, surgical glues, cyanoacrylates>

Dermal applications, prevalence for use of surgical sealants, glues, securement

pjd@mediligence.com — Tue, 13 Jan 2009 06:01:32 -0800

The blog on advanced medical technologies excerpts coverage of the dermal (skin repair) applications of surgical sealants and glues. These applications are prevalent and readily amenable to sealants and glues.

New Published Report from MedMarket Diligence: Surgical Sealants, Glues, Hemostasis and Wound Closure Market, 2009-2013

pjd@mediligence.com — Thu, 8 Jan 2009 10:43:27 -0800

Opportunities for products in wound closure, hemostasis and anti-adhesion products are plentiful for established and emerging companies, driven by innovation in product formulation and penetration of more caseload, including growth in more medical and surgical specialties. The market for these products is also growing through their expansion globally, with products being introduced and finding clinical acceptance in the U.S., Europe, Central and South America and other markets globally.

MedMarket Diligence tracks wound closure, hemostasis and anti-adhesion technologies and forecasts this market in a forthcoming worldwide report, with insight into market introduction, growth, competition and business opportunity. The 2009 report details the markets worldwide, with detailed geographic segmentation, for surgical sealants, glues, hemostats, sutures, tapes, other wound closure technologies and products in the prevention of post-surgical adhesion.

The report is entitled, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013."

The report is detailed here and may be ordered by order form or via online order for immediate download.

Tags: medtech, surgical sealants, fibrin sealants, surgical glues, cyanoacrylates>

High growth geographic markets in ablation technologies

patrick@mediligence.com — Mon, 8 Dec 2008 17:37:37 -0800

Review of "Worldwide Ablation Technologies Markets", Report #A125 from MedMarket Diligence reveal where the high growth geographic markets are for ablation technologies.

For a complete listing of MedMarket Diligence reports, see link.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: medtech, ablation, cryoablation, microwave, rf ablation>

Top New Medical Technologies and/or Platforms

patrick@mediligence.com — Sun, 23 Nov 2008 19:40:31 -0800

Review of top new medical technologies and/or platforms. Subject of MedMarket Diligence White Paper discussed in recent "advanced medical technologies" blog. Technologies include drug-device hybrids, RFID, ablation, tissue engineering, bioresorbables, and others.

For a complete listing of MedMarket Diligence reports, see link. See also the Medtech Startups Database.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: medtech, innovation, biotech>

Companies in Surgical Sealants, Glues, Wound Closure, Anti-Adhesion, Worldwide; New 2009 MedMarket Diligence Report

patrick@mediligence.com — Thu, 20 Nov 2008 11:00:26 -0800

The number of companies active in marketing and/or developing products in surgical sealants, glues, wound closure and anti-adhesion is testimony to the opportunity in this growth arena.

Below is a selection of companies profiled in the December 2008 report:

3DM, Inc. (3D-Matrix, Ltd.), Abbott Vascular, AccessClosure, Inc., Adhezion Biomedical, LLC , Advanced Medical Solutions , Angiotech Pharmaceuticals, Inc., Anika Therapeutics, Inc., ARC Pharmaceuticals Inc., Arch Therapeutics (formerly Clear Nano Solutions), ArthroCare Corporation, B. Braun Melsungen AG, Bard Medical Division, CR Bard, Baxter International Inc., Bayer Schering Pharma, BD (Becton Dickinson and Company), Biiosyntech Inc., Biocoral Inc, Biogentis, Inc., BIOSTER a.s., Cardiovascular Sciences, Inc., Cardiva Medical, Inc., Ceremed, Inc., Chemence Ltd., Cohera Medical, Inc., Collagen Matrix, Inc., Covidien, CryoLife, Inc., CSIRO PhotoMedical Technologies, CSL Behring, CSMG, Inc., CuraMedical BV, DePuy, Inc., Entegrion, Ethicon, Inc., Johnson & Johnson, FibroGen, Inc., Fidia Advanced Biopolymers SpA, Flamel Technologies SA, Focal, Inc., Forticell Bioscience, FzioMed, Inc., GEM s.r.l., Genzyme Biosurgery, GluStitch, Inc., Haemacure Corporation, Harvest Technologies Corporation, HemCon, Inc., Hemostasis LLC, Henkel Loctite Corp., HyperBranch Medical Technology, Inc., Innovasa Corporation, Integra Lifesciences Corporation, Interpore Cross International, Isto Technologies, Inc., I-Therapeutix, Inc., Kaketsuken (Chemo-Sero-Therapeutic Research Institute), Kensey Nash Corporation, Kimberly-Clark Health Care, King Pharmaceuticals, Inc., LifeBond, Ltd., Lifecore Biomedical Inc., Marine Polymer Technologies, Medafor, Inc., MedTrade Products, Meyer-Haake GmbH Medical Innovations, Morris Innovative, Neose Technologies, Nycomed Pharma AS, Omrix Biopharmaceuticals Inc., Organogenesis, Inc., Pharming Group NV, Plasma Technologies, Inc., PlasmaSeal LLC, Pluromed, Inc., Polyganics, BV, ProFibrix BV, Protein Polymer Technologies, Inc., Radi Medical Systems AB, Scion Cardio-Vascular, Inc., Sea Run Holdings, Smith & Nephew Plc , Sutura Inc., Synovis Life Technologies, Inc., Teleflex Medical, ThermoGenesis Corp., Therus Corporation, Thrombotargets Corp., Tissuemed Ltd., TraumaCure, Inc., TyRx Pharma, Inc. , Vascular Solutions, Inc. , Vectura Group plc , Vivostat A/S, Z-Medica Corp. The MedMarket Diligence report #S175, "Worldwide Surgical Sealants, Glues and Wound Closure Market, 2009-2013," is described at this link including details on the advanced purchase discount.

For a complete listing of MedMarket Diligence reports, see link. See also the Medtech Startups Database.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Surgical Sealants, Glues, Wound Closure, Anti-Adhesion, Worldwide; New 2009 MedMarket Diligence Report

patrick@mediligence.com — Thu, 20 Nov 2008 10:48:22 -0800

MedMarket Diligence's forthcoming (December 2008) report on surgical sealants, glues, wound closure and anti-adhesion details a dynamic market for products worldwide that are progressively becoming a mainstay of surgical and medical care across a wide range of clinical specialties.

"Worldwide Surgical Sealants, Glues and Wound Closure Market, 2009-2013." See link for details and advanced purchase discount.

For a complete listing of MedMarket Diligence reports, see link. See also the Medtech Startups Database.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgical sealant, surgical glue, fibrin sealant, fibrin glue, medical glue, medical adhesive, anti-adhesion>

Reports on advanced medical technologies: sealants/wound closure, ablation technologies, spine surgery, wound management, others

patrick@mediligence.com — Fri, 14 Nov 2008 11:45:09 -0800

A range of new medical technology market analyses are available, with another pending, from MedMarket Diligence. These worldwide reports detail advanced medical technologies with worldwide scope on the products, technologies, markets and opportunities.

"Worldwide Surgical Sealants, Glues and Wound Closure Market, 2009-2013." See link for details and advanced purchase discount.

"Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities." See link for details.

"Spine Surgery Worldwide 2008-2017, 2007-2016: Products, Technologies, Markets and Opportunities." See link for
details.

"Worldwide Wound Management, 2007-2016: Established and Emerging Products, Technologies and markets in the U.S., Europe, Japan and Rest of World." See link for details.

"Worldwide Market for the Clinical Management of Obesity, 2007-2015." See link for details.

For a complete listing of MedMarket Diligence reports, see link. See also the Medtech Startups Database.

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: ablation, rf ablation, microwave, ultrasound, HIFU, laser>

Ablation: Radiofrequency Among Big Growth Segments in Surgery

patrick@mediligence.com — Tue, 11 Nov 2008 16:07:26 -0800

The surgical ablation of soft tissues will see significant growth in the next few years and, among the different modalities employed, radiofrequency will demonstrate some of the most significant growth.

Growth among the ablation technology segments and a focus on radiofrequency are highlights of a recent "advanced medical technologies blog.

Ablation Technologies are the focus of a global report from MedMarket Diligence. Report #A125, entitled, "Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities," is described at this link and is available for purchase and immediate download online.

Tags: ablation, rf ablation, microwave, ultrasound, HIFU, laser>

Medical technology opportunities are many

patrick@mediligence.com — Fri, 7 Nov 2008 08:47:40 -0800

The downturn in the world economy, stemming as it does from overextended credit, including but not limited to bad lending in sub-prime mortgages, has no direct relevance for medical technology markets, which have numerous high growth segments. These offer very attractive opportunities for the medtech industry.

Segments with high growth are replete in ablation technologies, wound management, obesity management, spine surgery and others.

High growth segments are reviewed in the recent advanced medical technologies blog.

Tags: obesity, wound management, ablation, spine surgery

New medical technologies

patrick@mediligence.com — Tue, 28 Oct 2008 21:34:01 -0700

Selected companies are identified and their product/technology descriptions provided, from the Medtech Startups Database from MedMarket Diligence.

The Medtech Startups Database is described here. Technologies at startups are described, for recent months, here. To subscribe to the Medtech Startups Database, please do so online.

Recent and forthcoming reports from MedMarket Diligence:

Coming in December: Report #S175, "Worldwide Surgical Sealants, Glues and Wound Closure, 2009-2013."

Report #A125, "Ablation Technologies Worldwide: Products, Technologies, Markets, Companies and Opportunities."

Report #M510, "Spine Surgery Worldwide, 2008-2017: Products, Technologies, Markets and Opportunities."

Tags: startup,sealant, cyanoacrylate, fibrin, suture, hemostat, anti-adhesion, ablation, spine

Anti-adhesion, fibrin sealant, or both?

patrick@mediligence.com — Tue, 28 Oct 2008 06:47:33 -0700

Recent (fall 2008) clinical data is supporting the unusual premise that fibrin sealants, used for the sealing, closure and hemostasis of wounds, may also, when used appropriately, reduce the incidence, extent and severity of post-surgical adhesions. Clinical data from Haemacure's fibrin sealant, and similar investigative work by Angiotech on its CoSeal product, have opened up considerable new potential for these products in the large and largely unfulfilled market for anti-adhesion.

Sealants and securement products (encompassing sutures and staples, tapes, haemostats, sealants, high strength glues, and adhesion prevention products) offer distinct clinical and economic benefits. The clinical efficacy and cost benefits of using sealant and securement products are reviewed in the "advanced medical technologies" blog. This is also covered in Report #S175, "Worldwide Surgical Sealants, Glues and Wound Closure, 2009-2013."

Tags: sealant, cyanoacrylate, fibrin, suture, hemostat, anti-adhesion

U.S. Will Continue to Lead the Worldwide Bariatric Device Market

patrick@mediligence.com — Tue, 21 Oct 2008 10:11:08 -0700

The US and Canadian market for bariatric devices is growing at stunning rate, driven by an increasingly prevalent patient population, the increasing capability of physicians to perform bariatric procedures and a recognition by healthcare systems and third party payers to address the problem as a lynchpin for a condition that otherwise will drive up other, related healthcare costs. See blog and MedMarket Diligence Report #S825 on Obesity.

Tags: obesity, bariatric

In Asia/Pacific, China Dominates Conversation While Japan Dominates Markets

patrick@mediligence.com — Thu, 16 Oct 2008 22:04:28 -0700

Looking beyond the U.S. borders as well as the increasingly strong European Union, the conversation about large, growing markets frequently turns to the Asia/Pacific in general and to China in particular. But, according to a report from MedMarket Diligence, the market with greater growth and near term potential is instead Japan. See the attached forecast of the shares of the Asia/Pacific market for ablation technologies by China, Japan, India and Australia.

The worldwide market for ablation and other energy-based technologies is detailed in the new market and technology report, "Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities", from MedMarket Diligence, LLC

The report is described detail, with table of contents and list of exhibits, here.

Companies Developing and Marketing Ablation Technologies

patrick@mediligence.com — Thu, 16 Oct 2008 17:32:48 -0700

Given the breadth and depth of applications in ablation technologies, which encompass cardiology, oncology, general surgery, gynecology, orthopedics and other clinical areas, and which include technologies as diverse as microwave, cryotherapy, radiofrequency, laser, ultrasound, thermal, hydromechanical, and electrical, it is no surprise that a large and diverse group of companies are active in the market.

Below is a selection of companies covered in the MedMarket Diligence Report #A125, "Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities." (Published September 2008)

Abla-Tx Inc., Accuray, Accuray Inc., ACMI/Gyrus/Olympus, Acoustic MedSystems, AFx (Guidant), Alcon, Alcon Laboratories, Inc., American Medical Systems, Inc., AngioDynamics, Inc., ArthroCare Corporation, ATI Medical, Inc., AtriCure, Inc., ATS Medical, Bard Electrophysiology, Bard EP, Bausch & Lomb, Bausch & Lomb (Warburg Pincus), Baylis Medical Company Inc., Biomet, Inc., Biosense Webster, Inc., BIOTRONIK GmbH & Co. KG, Biowave Corporation, Boston Scientific Corporation, C. R. Bard, Inc., Candela Corporation, Cardima, Inc., Cardiogenesis Corporation, Celon AG medical instruments, Celsion Corporation, ConMed Corporation, Covidien Ltd., CryoCath Technologies Inc., CryoCor, Inc., CSA Medical, Inc., Cytyc Corporation, Dornier MedTech, EDAP TMS S.A., Edwards Lifesciences Corp., Elekta AB, Endocare, Inc., ERBE Elektromedizin GmbH, Erbe USA, Inc., Ethicon Endo-Surgery, Inc., Galil Medical Inc., Getinge AB, Guidant Corporation, Gynecare, Gyrus ACMI, Inc., HealthTronics, Inc., Integra Radionics, Inc., Light Sciences Corporation, Lumenis Inc., Maquet GmbH & Co. KG, Medtronic, Medtronic, Inc, MedWaves, Inc., Mirabilis Medica, Misonix, Inc., Mitek Products, NeuWave Medical Inc., Olympus Medical, Olympus Optical Company Ltd., OmniSonics Medical Technologies, Inc., Oncura, PhotoMedex, Inc., PhotoThera, Inc., PhotoTherapeutics Inc., ProSurg, Inc., Proxima Therapeutics, Inc., Radionics, RFA Medical, Inc., Sanarus Medical, Inc., SenoRx, Inc., Siemens Medical Solutions USA, Inc., Smith & Nephew plc, Spectranetics, St. Jude Medical, Inc., Starion Instruments Corporation, Stereotaxis, Inc., Stryker Instruments, Theragenics Corporation, TissueLink Medical, Inc., Urologix, Inc., USHIFU, Valleylab, Varian Medical Systems, Inc., VISX, Vivant Medical, VNUS Medical Technologies, Inc.

The complete report on the Worldwide Ablation Technologies Market is described, with complete table of contents and list of exhibits, here.

Tags: ablation, rf ablation, microwave, ultrasound, HIFU, laser>

Spine Surgery Companies Take Advantage of Report Opportunity

patrick@mediligence.com — Wed, 15 Oct 2008 16:50:13 -0700

MedMarket Diligence has completed a worldwide analysis of spine surgery. Any company among the following who contacts us by email (reports(at)mediligence(dot)com) from a company email address will receive a reply back from us with an attractive offer to receive the Report #M510, "Spine Surgery: Products, Technologies, Markets & Opportunities Worldwide, 2008-2017."

Abbott Spine, AlloSource, Alphatec Holdings, Inc., Altiva Corporation, Anulex Technologies, Inc., ApaTech, Applied Spine Technologies, A-Spine Holding Group Corporation, Axial Biotech, AxioMed Spine Corporation, B. Braun/Aesculap, Inc., BioAssets Development Corporation, Biomet, Biorthex, Inc., Blackstone Medical, Inc, BrainLAB, Cardinal Health, Cervitech, Changzhou Kanghui, Co.Don AG, CoLigne AG, Cook Group, CoreSpine Technologies LLC, Corin Group, Cortek, Inc, Cryolife, Inc., Cyberkinetics Neurotechnology Systems, DePuy Spine/J&J, Disc Dynamics, Disc Motion Technologies, Encore Medical Corporation, Facet Solutions, Fixano, GE Healthcare, Gentis, Inc, Globus Medical, GMReis, HydroCision, Innovative Spinal Technologies, Integra LifeSciences, Integra Radionics, Interpore Cross, Interventional Spine, Invibio, LDR Holding Corporation, LifeNet Health, Inc., MacroPore Biosurgery Inc, Mazor Surgical Technologies Ltd, Medtronic, Inc, Medtronic Sofamor Danek, Medtronic Surgical Navigation, Mekanika, Inc., Merck & Co., Inc., MiMedx, Misonix, MTF (Musculoskeletal Transplant Foundation), NPS Pharmaceuticals, N Spine, Inc., NuVasive, Inc., Ortho Development Corporation, Orthofix International, N.V., OrthoVita, Osiris Therapeutics, Osteotech, Inc., Ortosintese, Paradigm Spine, LLC, Pitkar, Praxim, Ranier Technology Limited, Raymedica, Inc., Regeneration Technologies, Inc, Scient’X, SeaSpine, Inc., Sharma Surgical, Small Bone Innovations, LLC, Smart Disc, Smith & Nephew, SpinalMotion, SpineMedica Corporation, Spineology, SpineOvations, SpineVision Inc, Spine Wave, Inc., Stryker Corporation, Stryker Instruments, Stryker Spine, Synthes Spine Solutions, Theken Spine, TranS1, Inc., Trimedyne, Inc., Ulrich Medical GmbH, Valleylab, Vertebron Inc., Waston Medical, Wright Medical Technology, X-spine Systems, Inc., Zimmer Spine

Key Ablation Technology Companies

patrick@mediligence.com — Tue, 14 Oct 2008 20:58:13 -0700

The energy-based medical device industry is led by a diverse group of companies, including small-to-medium pure-play companies specializing in ablation therapies and large multinationals whose interests encompass other classes of medical devices as well as ablation products. The worldwide market for ablation and other energy-based technologies is detailed in the new market and technology report, "Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities", from MedMarket Diligence, LLC

The report is described detail, with table of contents and list of exhibits, here.

Wound Management Products Market Growth, Up and Down, to 2016

patrick@mediligence.com — Tue, 14 Oct 2008 10:00:41 -0700

Technologies developed and in use for the management of acute and chronic wounds have diversified from traditional dressings, bandages and wound closure techniques to include an increasing number of diverse technologies ranging from tissue engineering, growth factors, physical therapies (e.g., negative pressure) and others. Traditional dressings and bandages have evolved to contain more active elements contributing to wound healing, with products including films, hydrocolloids, foams, alginates, hydrogels, non-adherents and antimicrobials.
The advanced medical technologies blog details the different segment growth rates within the worldwide wound management market.

Wound management is the focus of the comprehensive MedMarket Diligence report #S245, "Worldwide Wound Management, 2007-2016". See link for details. This report may be purchased online.

Tags: wound-management, wound dressing>

Obesity Management Worldwide Market Size, Forecast and Technology Opportunities Detailed in Report on Drugs and Devices in the Clinical Management of Obesity

patrick@mediligence.com — Mon, 13 Oct 2008 11:48:51 -0700

As the growing worldwide problem of obesity becomes more evident, including its commensurate healthcare costs, there is a coinciding proliferation of the number and type of approaches to address the problem. MedMarket Diligence's global analysis of the caseload, incidence/prevalence, clinical practice trends, products in development and on the market, current/forecast market, competitor shares and company profiles is a detailed and valuable framework for any current or potential medtech innovator seeking to compete in the worldwide market for the clinical management of obesity.

The report is described, with full table of contents and list of exhibits, here.

The report can also be ordered online here.

Tags: obesity, bariatric,>

The Uses of Adjunctive Surgical Closure and Sealant Products

patrick@mediligence.com — Sat, 11 Oct 2008 12:28:59 -0700

Sealants and securement products (encompassing sutures and staples, tapes, haemostats, sealants, high strength glues, and adhesion prevention products) offer distinct clinical and economic benefits. The clinical efficacy and cost benefits of using sealant and securement products are reviewed in the "advanced medical technologies" blog. This is also covered in Report #S145, "Worldwide Surgical Sealants, Glues and Wound Closure, 2007-2011."

Tags: sealant, cyanoacrylate, fibrin, suture, hemostat>

Spine Surgery Technologies Demonstrating Robust Worldwide Market Growth and Market Evolution

patrick@mediligence.com — Fri, 10 Oct 2008 10:32:46 -0700

Among the most device-intensive healthcare markets, the spine surgery market has been undergoing dramatic changes as numerous new technologies take hold in the well established spine surgery surgical arena and manufacturers continue to develop new technologies and roll them out for a growing patient population. Globally, the market will grow to over $26 billion over the next ten years, demonstrating double digit growth in the process. The MedMarket Diligence report on spine surgery details the products, technologies, markets and companies worldwide.

The MedMarket Diligence report on the "Worldwide Spine Surgery Market" is described here. and is available for purchase and immediate download here.

Tags: spine surgery, disc replacement, spine fusion, interbody fusion>

Spine surgery technology segment growth rates

patrick@mediligence.com — Wed, 8 Oct 2008 14:44:04 -0700

Spine surgery represents a relatively unique medical technology market, in an era of declining margins and overall cost containment, that is both device-intensive and demonstrating aggressive growth.

Growth in specific segments of the spine surgery technology market is illustrated in the recent "advanced medical technologies" blog. The MedMarket Diligence report on the "Worldwide Spine Surgery Market" is described here.

Tags: spine, disc replacement, interbody fusion>

Medtech startups by clinical/technology segment

patrick@mediligence.com — Wed, 8 Oct 2008 14:32:36 -0700

Activity remains high in the formation of startups in medical technology. Hundreds of medtech companies have been formed in the past few years with areas of focus filling the range from cardiology to wound management and from traditional devices to a dizzying array of product types that defy attempts at categorization.

Company formations in medical technology are summarized in the recent advanced medical technologies blog and the Medtech Startups Database is described here.

Tags: startups, medtech, medical technology>

Rapid Growth in Asia-Pacific Spine Surgery Technology Markets

patrick@mediligence.com — Wed, 1 Oct 2008 12:22:52 -0700

The Asia-Pacific spine surgery market is growing rapidly, at an estimated compound annual growth rate of 18%. The market is therefore expected to more than quadruple in size by the end of the forecast period.

The advanced medical technologies blog highlights the market for spine surgery products and technologies in Japan, Korea and Australia, drawn from the 2008 report, "Worldwide Spine Surgery 2008-2017," report #M510, published by MedMarket Diligence.

Energy-Based Device Markets: Ablation Technologies, Share by Segment and Country/Region

patrick@mediligence.com — Thu, 25 Sep 2008 21:22:15 -0700

The worldwide high energy therapies market represents a $25 billion opportunity in 2008. The category consists of therapeutic devices and equipment that deliver the controlled application of one or more modalities of energy to tissue. The worldwide market for ablation and other energy-based technologies is the subject of a new market and technology report, "Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities", from MedMarket Diligence, LLC . The report details the products on the market, products in development and analysis of the market by technology (electrical, radiation, light, radiofrequency, cryotherapy, thermal, microwave, and hydromechanical) and by country/region: Americas (USA, Canada, Mexico, Brazil), Europe (Germany, United Kingdom, France, Italy, Spain, BeNeLux), Asia/Pacific (Japan, China, India, Australia) and Rest of World.

The report is described detail, with table of contents and list of exhibits, here.

The report may be ordered online here or via order form attached (also here).>

Ablation Technologies and Other Energy-Based Therapies Proliferating Worldwide

patrick@mediligence.com — Fri, 12 Sep 2008 15:38:13 -0700

The global market for ablation and other energy-based therapeutics is swelling at double digit growth rates, with revenues in some energy types growing at or beyond 20% annually. The efficacy of different modalities in achieving different clinical end-points (cutting, coagulating, excising tissue, creating anti-arrhythmic lesions, etc.) is increasing with new product developments and products are being more readily adopted by clinicians becoming facile with their use. The worldwide market for ablation and other energy-based technologies is the subject of a new market and technology report, "Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities", from MedMarket Diligence, LLC

The report is described detail, with table of contents and list of exhibits, here.

Wound Management Market Segment Growth, 2008-2017

patrick@mediligence.com — Sat, 23 Aug 2008 08:00:13 -0700

Wound management is the focus of the comprehensive MedMarket Diligence report #S245, "Worldwide Wound Management, 2007-2016". See link for details.

Spine fusion companies, by technology

patrick@mediligence.com — Fri, 22 Aug 2008 10:58:38 -0700

Surgeons performing instrumented spinal fusion procedures implant various configurations of plates, rods, screws, cages, and other medical hardware to stabilize the spine and facilitate proper vertebral bone fusion. Recent blog "advanced medical technologies" details spine fusion technologies and active companies, by technology.

Spine surgery (worldwide) is also the subject of a 2008 report from MedMarket Diligence, See link for description and table of contents.

Ablation: An Energized Market

patrick@mediligence.com — Tue, 19 Aug 2008 08:15:32 -0700

Energy-based therapies generate sales of $13 billion in the United States alone, with probably another $12 billion in other developed markets worldwide. This represents around 13% of the total medical device market, and it is growing at 11% per annum --- twice the growth rate for medical devices overall.

Ablation and other energy-based technologies are discussed in recent mediligence.com/blog posts.

Ablation is the subject of a forthcoming report from MedMarket Diligence, "Ablation Technologies Worldwide Market." See link for description and table of contents.

Top Line Market Data Released in Selected Executive Summaries from MedMarket Diligence Reports

patrick@mediligence.com — Fri, 13 Jun 2008 08:07:09 -0700

MedMarket Diligence (MMD) is now making available the executive summaries -- top line data on products, technologies, companies, markets, and opportunities -- from selected MMD Reports:

Spine Surgery Worldwide 2008-2017. See link for full report details.
Ophthalmology 2007 Worldwide. See link for full report details.
Wound Management Worldwide 2007-2016. See link for full report details.
Obesity Management Worldwide 2007. See link for full report details.
Diabetes Worldwide 2005-2015. See link for full report details.

For ordering any of these executive summaries, go to link. For additional details, contact Patrick Driscoll at (949) 859-3401 or patrick mediligence com.>

Spine Surgery Steadily Adopting Minimally Invasive Procedures (MedMarket Diligence Report)

patrick@mediligence.com — Fri, 6 Jun 2008 08:25:29 -0700

The development of imaging systems like fluoroscopy, sophisticated endoscopes and a wide range of surgical instruments that facilitate minimally invasive surgery are combining with the persistent demand for less invasive, less traumatic procedures to drive the growth of minimally invasive spine surgery. Products, technologies and trends in minimally invasive surgery are detailed in the worldwide spine surgery report from MedMarket Diligence.

The report #M510 on "Spine Surgery Worldwide" is described, with complete table of contents and list of exhibits, at link.

Tags: spine, degenerative disc, interbody fusion, artificial disc>

Obesity: Products, Technologies, Markets and Companies in the Clinical Management of Obesity Worldwide (MMD Report)

patrick@mediligence.com — Thu, 29 May 2008 15:07:53 -0700

Technologies for the management of obesity span surgical approaches, medically supervised diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. MedMarket Diligence's global analysis of the caseload, incidence/prevalence, clinical practice trends, products in development and on the market, current/forecast market, competitor shares and company profiles is a detailed and valuable framework for any current or potential medtech innovator seeking to compete in the worldwide market for the clinical management of obesity.

The report is described, with full table of contents and list of exhibits, here.

The report can also be ordered online here.

Tags: obesity, bariatric,>

Opportunities in wound closure, hemostasis and anti-adhesion, worldwide

patrick@mediligence.com — Thu, 29 May 2008 14:30:57 -0700

Significant opportunities for products in wound closure, hemostasis and anti-adhesion products continue to be available for established and emerging companies, driven by innovation in the products themselves and penetration of more caseload, including growth in more medical and surgical specialties. The market for these products is also growing through their expansion globally, with products being introduced and finding clinical acceptance in the U.S., Europe, Central and South America elsewhere in the world.

The applications, products, technologies and markets are also the subject of a definitive MedMarket Diligence report, "Worldwide Sealants, Glues & Wound Closure, 2007-2011."

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online here.

See also the 2007 report, "Worldwide Wound Management, 2007-2016," with detailed table of contents and list of exhibits, here.>

Sealants, Glues, Hemostasis, and Securement Uses Support Intense Competitive Activity and Accelerated Market Growth

patrick@mediligence.com — Wed, 28 May 2008 11:43:45 -0700

The applications and the benefits of medical/surgical sealants, hemostatics, closure and anti-adhesion are discussed in a recent post on the advanced medical technologies blog. These benefits are the reason behind intense competitive interest and the accelerated market growth of these products.

The applications, products, technologies and markets are also the subject of a definitive MedMarket Diligence report, "Worldwide Sealants, Glues & Wound Closure, 2007-2011."

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online here.>

Medical and Surgical Glues, Sealants, Hemostasis and Wound Closure by Region/Country

patrick@mediligence.com — Fri, 16 May 2008 10:29:02 -0700

Medical and surgical glues, sealants, hemostasis and wound closure products, products under development, current/forecast market and market shares and other data and insights reveal opportunities in these markets globally through the 2007 MedMarket Diligence report, "Wordwide Surgical Sealants, Glues and Wound Closure 2007." Caseload volumes, current markets globally (by region and country), new product development status detail, local/regional clinical practice trends, competitor shares and other hard data reveal opportunities in the worldwide market. This report has become a definitive source of data and insights for leading and emerging contenders in the markets for sealants/glues/wound closure.

Products covered: Sutures and staples, tapes, hemostats, fibrin and sealant products and medical adhesives.

Geographic detail: U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan and Rest of World

The report is described, with full table of contents and list of exhibits, here. The report can be ordered online here.>

"Worldwide Wound Management 2007-2016" MedMarket Diligence

patrick@mediligence.com — Thu, 8 May 2008 10:00:49 -0700

Products in wound management span simple dressings and bandages to advanced biotech, mechanical and other technologies designed to facilitate and accelerate the wound healing process. The combined nature of the resulting product market -- from well established high volume sectors to rapid growth emerging sectors -- represents enormous business potential for current and prospective wound management companies. MedMarket Diligence's report, "Worldwide Wound Management 2007-2016", publishing November 2007, details the products, technologies, markets and companies worldwide in the wound management industry.

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online.

Tags: wound>

Spine Surgery Worldwide Market Characterized by Many New Technologies, Changing Clinical Practice Dynamics and Double Digit Growth, According to New Report from MedMarket Diligence, LLC

patrick@mediligence.com — Tue, 6 May 2008 15:41:22 -0700

Among the most device-intensive healthcare markets, the spine surgery market has been undergoing dramatic changes as numerous new technologies take hold in the well established spine surgery surgical arena and manufacturers continue to develop new technologies and roll them out for a growing patient population. Globally, the market will grow to over $26 billion over the next ten years, demonstrating double digit growth in the process. A new report from MedMarket Diligence, "Spine Surgery: Products, Technologies, Markets & Opportunities, Worldwide, 2008-2017", details the products, technologies, markets and companies worldwide.

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online.

Tags: spine, degenerative disc, interbody fusion, artificial disc>

Key Facts in the Worldwide Spine Surgery Market

patrick@mediligence.com — Wed, 30 Apr 2008 13:01:06 -0700

Striking facts about the worldwide spine surgery market, covered in report #M510 from MedMarket Diligence, LLC:

Seven of eight technology market segments within spine surgery show double-digit compound growth rates through 2017.

Three (almost four) of the eight technology market segments within spine surgery show compound growth rates in excess of 20% through 2017

The U.S. accounts for 76% of the worldwide spine surgery market

At least 38 companies have been founded in the spine surgery arena since 2002.

Spine Surgery Worldwide Report: Robust and Growing List of Companies Active in Spine Surgery According to New Report from MedMarket Diligence, LLC

patrick@mediligence.com — Mon, 31 Mar 2008 13:10:25 -0700

Companies active in the marketing and development of spine surgery technologies have grown in number in recent years as the growing caseload, expanding capabilities of new techniques and technologies, and the rapid adoption by spine surgeons are driving attractive market growth for current and hopeful market competitors.
Companies in spinal technology market development and address in the MedMarket Diligence report #M510 include the following:

Abbott Spine, Alphatec Holdings, Inc., Anulex Technologies, Inc., Applied Spine Technologies, A-Spine Holding Group Corporation, AxioMed Spine Corporation, BioAssets Development Corporation, Biorthex, Inc., BrainLAB, Cervitech, Co.Don AG, Cook Group, Corin Group, Cryolife, Inc., Cytori Therapeutics, Disc Dynamics, Encore Medical Corporation, Fixano, Gentis, Inc, GMReis, Innovative Spinal Technologies, Integra Radionics, Interventional Spine, LDR Holding Corporation, Mazor Surgical Technologies Ltd, Medtronic Sofamor Danek, Mekanika, Inc., MiMedx, MTF (Musculoskeletal Transplant Foundation), N Spine, Inc. (Synthes), Ortho Development Corporation, OrthoVita, Osteotech, Inc., Paradigm Spine, LLC, Praxim, Raymedica, Inc., Scient’X, Sharma Surgical, Smart Disc, SpinalMotion, Spineology, SpineVision Inc, Stryker Corporation, Stryker Spine, Theken Spine, Trimedyne, Inc., Valleylab, Waston Medical, X-spine Systems, Inc., AlloSource, Altiva Corporation, ApaTech, ArthroCare Corporation, Axial Biotech, B. Braun/Aesculap, Inc., Biomet, Blackstone Medical, Inc, Cardinal Health, Changzhou Kanghui, CoLigne AG, CoreSpine Technologies LLC, Cortek, Inc, Cyberkinetics Neurotechnology Systems, DePuy Spine/J&J, Disc Motion Technologies, Facet Solutions, GE Healthcare, Globus Medical, HydroCision, Integra LifeSciences, Interpore Cross, Invibio, LifeNet Health, Inc., Medtronic, Inc, Medtronic Surgical Navigation, Merck & Co., Inc., Misonix, NPS Pharmaceuticals, NuVasive, Inc., Orthofix International, N.V., Osiris Therapeutics, Ortosintese, Pitkar, Ranier Technology Limited, Regeneration Technologies, Inc, SeaSpine, Inc., Small Bone Innovations, LLC, Smith & Nephew, SpineMedica Corporation, SpineOvations, Spine Wave, Inc., Stryker Instruments, Synthes Spine Solutions, TranS1, Inc., Ulrich Medical GmbH, Vertebron Inc., Wright Medical Technology, Zimmer Spine

Worldwide Spine Surgery Market Characterized by Many New Technologies, Dynamics and Double Digit Growth, According to New Report from MedMarket Diligence, LLC

patrick@mediligence.com — Wed, 12 Mar 2008 15:59:26 -0700

Among the most device-intensive healthcare markets, the spine surgery market has been undergoing dramatic changes as numerous new technologies take hold in the well established spine surgery surgical arena and manufacturers continue to develop new technologies and roll them out for a growing patient population. Globally, the market will grow to over $26 billion over the next ten years, demonstrating double digit growth in the process. A new report from MedMarket Diligence, "Spine Surgery: Products, Technologies, Markets & Opportunities, Worldwide, 2008-2017", details the products, technologies, markets and companies worldwide.

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online.

Tags: spine, degenerative disc, interbody fusion, artificial disc>

Wound Types and Advanced Wound Products, Worldwide (MedMarket Diligence report #S245)

patrick@mediligence.com — Mon, 7 Jan 2008 11:39:59 -0800

The worldwide wound management market stood at $4.6 billion in 2007 and will reach $11.5 billion by 2016. As one of the most technologically diverse areas of medicine, products in wound management span simple dressings and bandages to advanced biotech, mechanical and other technologies designed to facilitate and accelerate the wound healing process. The combined nature of the resulting product market -- from well established high volume sectors to rapid growth emerging sectors -- represents enormous business potential for current and prospective wound management companies. MedMarket Diligence's report, "Worldwide Wound Management 2007-2016: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World", published November 2007, details the products, technologies, markets and companies worldwide in the wound management industry.

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online.

Tags: wound>

Published: "Worldwide Wound Management 2007-2016" New Report from MedMarket Diligence

patrick@mediligence.com — Mon, 26 Nov 2007 13:12:06 -0800

Worldwide Wound Management 2007-2016: New Report from MedMarket Diligence

patrick@mediligence.com — Thu, 8 Nov 2007 08:51:17 -0800

Drugs and Devices in the Clinical Management of Obesity Worldwide; New Report from MedMarket Diligence, LLC

patrick@mediligence.com — Thu, 20 Sep 2007 13:10:15 -0700

As the growing worldwide problem of obesity becomes more evident, including its commensurate healthcare costs, there is a coinciding proliferation of the number and type of approaches to address the problem. Clinical practices, products, technologies, companies and markets worldwide in the clinical management of obesity are detailed in a newly published report from MedMarket Diligence, "Worldwide Market for the Clinical Management of Obesity, 2007-2015."

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online.

Tags: obesity, bariatric, lapband>

Obesity Drug and Device Markets Matching Growth in Obesity Prevalence

patrick@mediligence.com — Fri, 31 Aug 2007 14:03:06 -0700

The numbers in the obesity population continue to go grow and, with the aggressive development by manufacturers of myriad drug, device and other solutions to the clinical problem, the market for these products is matching that growth. The current clinical practices, procedures, products and their associated markets are the subject of a new analysis by MedMarket Diligence, "Worldwide Market for the Clinical Management of Obesity, 2007."

The report is described, with full table of contents and list of exhibits, here.

The report can also be ordered online here.

Tags: obesity, bariatric, lapband>

Over 500 Medtech Startup Companies Identified

Tue, 4 Sep 2007 21:55:39 -0700

Over 500 companies represented in the Medtech Startup Companies Database from MedMarket Diligence comprise a robust range of new technologies --- and offer many opportunities for technology licensing, joint venture, investment and acquisition. Technologies under development include medical devices, diagnostics, drugs, biomaterials and others.

The database is described here.

For additional details, contact Patrick Driscoll of MedMarket Diligence, LLC. Tel: (949) 859-3401.

Tags: medtech, startups>

Global Statistics on Incidence, Prevalence in Ophthalmology; Country-Specific Markets Xand Competitor Shares

Tue, 31 Jul 2007 11:01:14 -0700

Worldwide Ophthalmology Market 2007
A report with worldwide scope from MedMarket Diligence details the incidence and prevalence in ophthalmology, with country-specific detail worldwide for vision disorders, keratoconus, glaucoma, cataract and retinal disorders. Based on primary and secondary research among clinicians, manufacturers and other market stakeholders worldwide, the report provides extensively detailed incidence, prevalence, market size, growth, and forecasted competitor shares per country and/or region for the United States, individual western European countries (UK, Germany, France, BeNeLux, Italy and Spain), Japan and other key international markets; Asia (India, Korea, Australia, Russia and China), other Americas (Canada, Mexico, Brazil) and Middle East and Africa categories.

The report is described with a detailed table of contents and list of exhibits here. The report is available for purchase online here.

Tags: medtech, ophthalmology>

Medical Technology Takes Turn Toward Hybrids, Increased Performance

Wed, 25 Jul 2007 15:10:06 -0700

If the types of technologies that are now under development at new medical technology startups are any indication, manufacturers are increasingly turning toward the addition of technologies that are complementary to devices in order to achieve gains in product performance.

New medical technologies under development at startups founded within the past 12 month shows the use of multiple different technologies to achieve improved clinical outcomes.

Companies and their technologies have been identified by MedMarket Diligence and are accessible via the Medtech Startups Database.

Tags: medtech, startups
>

Obesity 2007: Worldwide Market for the Clinical Management of Obesity, report from MedMarket Diligence, LLC

Sat, 7 Jul 2007 11:43:34 -0700

The clinical management of obesity represents a worldwide market --- encompassing devices, surgical procedures, drugs and other therapies --- that will surpass $5 billion by 2013. MedMarket Diligence has closely tracked this market and will release its 2007 analysis of the worldwide market for products in the clinical management of obesity.

Products to manage clinical obesity span surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The MedMarket Diligence report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy, and provides current and forecast of the market for these products in the U.S., Europe and Rest of World. The report profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management.

The Worldwide Market for the Clinical Management of Obesity, 2007 is described with table of contents at http://www.mediligence.com/rpt/rpt-s825.htm. The report may be ordered here or via order form.

Tags: medtech, obesity

See complete MMD report listing here.>

(UPDATE) Medtech Startup Companies Database (Nearly 500 Companies) now available from MedMarket Diligence, LLC

info@mediligence.com — Fri, 22 Jun 2007 10:43:33 -0700

MedMarket Diligence has introduced a new online database of startup medtech companies. Drawn from the ongoing research performed in support of the MedMarkets newsletter and market and technology Reports, the Medtech Startups Database is an online, boolean searchable database of new medical product companies spanning medical device, biotech, biomaterials, biopharm, and others competing in these often overlapping market.

The database, currently comprised of nearly 500 recent medtech startups, is updated each month with roughly 10 recently founded companies. Records on existing companies in the database are also reviewed on a regular basis to update company data. The companies in this database represent companies reported in the MedMarkets publication, with details as complete as possible on these frequently "stealth" companies, but also include other companies separately identified by MedMarket Diligence through its proprietary report and other research activities. Companies included span the medical device, biotech, biomaterial, pharmaceutical and other areas.

The Medtech Startups Database is an online database available through annual subscription options.

See http://www.mediligence.com/startups-db.htm for more details.

Tags: medtech, startups

See complete MMD Market and Technology Reports listing here.>

Medical/Surgical Glues and Sealants Have Firm Hold on Applications

Mon, 11 Jun 2007 13:27:41 -0700

A robust array of medical/surgical sealants, glues, and hemostatic agents are progressively taking hold of significant shares of caseload spanning many different clinical applications, from cardiovascular to orthopedic, neurological, urological, skin/integumentary, plastic surgery/aesthetics, and others. Products, technologies, indications, current/potential caseload and companies are detailed in the MedMarket Diligence report, "Worldwide Surgical Sealants, Glues and Wound Closure 2007."

Opportunities for products in wound closure, hemostasis and anti-adhesion products continue to be available for established and emerging companies, driven by innovation in the products themselves and penetration of more caseload, including growth in more medical and surgical specialties. The market for these products is also growing through their expansion globally, with products being introduced and finding clinical acceptance in the U.S., Europe, Central and South America elsewhere in the world.

See the full MedMarket Diligence report, with description and table of contents at http://www.mediligence.com/rpt/rpt-s145.htm.

Worldwide Surgical Sealants, Glues and Wound Closure 2007 may be purchased here.

Tags: medtech, hemostats, sealants

See complete MMD report listing here.>

Report: Worldwide Surgical Sealants, Glues and Wound Closure 2007 Market

Fri, 11 May 2007 12:27:32 -0700

MedMarket Diligence has tracked the emergence and growth of novel technologies in wound closure, hemostasis and anti-adhesion over the past decade, providing insight into market introduction, growth, competition and opportunity through worldwide analysis. The products, markets and companies in this medical technology arena have now been analyzed in the detailed report from MedMarket Diligence. The 2007 report reveals the markets worldwide, with detailed forecasts of geographic segmentation, for surgical sealants, glues, hemostats, sutures, tapes and other wound closure technologies.

See the full report description and table of contents at http://www.mediligence.com/rpt/rpt-s145.htm.

Worldwide Surgical Sealants, Glues and Wound Closure 2007 may be purchased here.

Tags: medtech, hemostats, sealants

See complete MMD report listing here.>

Bone Grafts/Substitutes, Polymers, Ceramics, Growth Factors and Tissue Engineering in Orthopedics

Fri, 20 Apr 2007 07:42:22 -0700

The use of products collectively known as "orthopedic biomaterials" represents a growing share of clinical practice in orthopedics. Current uses, products on the market, new products under development and their sales in the worldwide market are detailed in a MedMarket Diligence report that reveals opportunities for competitors.

See the full report description and table of contents at http://www.mediligence.com/rpt/rpt-m625.htm.

Worldwide Orthopedic Biomaterials 2007 may be purchased here.

Tags: medtech, orthopedics, biomaterials

See complete MMD report listing here.>

Orthopedic Biomaterials: Products, Companies and Global Markets

Wed, 6 Dec 2006 07:25:53 -0800

A new MMD report details the current and emerging products and technologies in the global market for orthopedic biomaterials. Bone graft, bone substitutes, polymers, ceramics, bone growth factors, sealants/glues, anti-adhesion, tissue engineering and other products comprise this current $5 billion market worldwide.

The activities of 70 companies in this market are analyzed: Aastrom Biosciences, Inc., Absorbable Polymer International, Acologix Inc., Advanced Cell Technology Inc., Allograft Tissue Systems Inc (ATSI), Allosource, Alphatec Spine, Inc., Altiva Corporation, Amedica Corporation, Angstrom Medica Inc., ApaTech Ltd., Arthrex, Arthrotek, Artimplant, Berkeley Advanced Biomaterials Inc., Biocoat Inc., Biocomposites Ltd, Biocoral, Inc., BioMimetic Therapeutics Inc., Biopharm GmbH, BioSyntech Inc., CeramTec AG, CeraPedics LLC, Clearant Inc., Closure Medical Corporation, Cortek, Inc., Cryolife, Inc., De Puy Inc., Encelle Inc., Encore Medical, Enobia Pharma Inc., Etex Corporation., Fidia Advanced Biopolymers s.r.l., FzioMed Inc., Genzyme Biosurgery, Inc., Haemacure Corporation, Inion Ltd, Integra Lifesciences Holdings Corporation, Interpore Cross International, Invibio Material Solutions, Isotis, N.V., Isto Technologies Inc., Japan Medical Materials Corporation, LifeCell Corp., LifeNet Allografts, Medtronic Sofamor Danek, Metoxit AG, Morgan Advanced Ceramics, NovaBone Products LLC, Ortec International, Inc., OrthoLogic Corporation, Orthovita, Inc., Osiris Therapeutics Inc., OsteoBiologics Inc, Osteohealth Company, Osteotech, Inc., Protein Polymer Technologies Inc., Regen Biologics, Inc., Regeneration Technologies, Inc., Smith & Nephew, plc., Stryker Biotech, Synthes, Inc., TEI Biosciences, Teknimed SA, Tutogen Medical, Inc., Wright Medical Technology, Inc.

See the full report description and table of contents at www.mediligence.com.

Worldwide Orthopedic Biomaterials 2007 may be purchased here.

Tags: medtech, orthopedics, biomaterials

See complete MMD report listing here.>

Worldwide Market for Orthopedic Biomaterials (Report): Products, Markets, Shares and Outlook Globally (from MMD)

Wed, 6 Dec 2006 07:53:51 -0800

The orthopedic biomaterials market is an evolving arena in the development, adoption and/or evolving use of bone, bone substitutes, polymers, ceramics, bone growth factors, sealants/glues, anti-adhesion, tissue engineering and other products. The market is party to established orthopedic device manufacturers as well as niche biomaterials companies with innovative offerings. The resulting $5 billion current orthopedic biomaterials market will grow at double digit annual rates reaching nearly $10 billion by 2011. MedMarket Diligence has completed a global report on products, technologies, markets and players, with insights on the market's outlook.

The report description and table of contents may be viewed here.

Worldwide Orthopedic Biomaterials 2007 may be purchased here.

Tags: medtech, orthopedics, biomaterials

See complete MMD report listing here.>

Refractive Surgery, Cataract Surgery, Glaucoma Treatment, Other Ophthalmic Markets Detailed in Global Report from MMD

Mon, 4 Dec 2006 07:42:56 -0800

The products, technologies, markets and companies in the field of vision diagnostics, eye care products, cataract surgery, refractive surgery, glaucoma treatment, and treatment for back of the eye disorders are analyzed by sector and geographic segmentation in a new report from MMD (MedMarket Diligence).

Companies covered include: Acufocus, Addition Technology, Inc., Advanced Cell Tech, Inc., American Optisurgical, Inc. (AOI), Aquasys, Inc, BD Medical Ophthalmic, Biosyntrx, Inc., Calhoun Vision, CustomVis, Eagle Vision, Eli Lilly, Endo Optiks, Inc., Escalon Medical Imaging, EyeKon Medical, Eyemaginations, Eyeonics, Inc., EyeSys Vision, Inc., FCI Ophthalmics, Genentech, Geuder AG, Glaukos, Haag-Streit, Heidelberg Engineering, Inc., Heine, Howard Instruments, Huvitz, IOP, Inc., IRIDEX, iScience Interventional, ISTA Pharmaceuticals, Keeler Instruments, Kowa Optimed, Lacrimedics, Leica Microsystems, Lenstec Inc, Lumenis, MacuScope, MacuSight, Inc., Marco, Mastel Precision, Medennium, Micro Medical Devices, Inc, Moeller-Wedel., MST, Neitz Instruments Co, NeoMedix, NeoVista, New World Medical, Nidek, Inc., Novadaq Technologies, Novartis Ophthalmics, NovaVision Inc., OASIS Medical, OccuLogix, OculusGen Biomedical, Odyssey Medical, Omni Lens, Ophtec, Optikon 2000 s.p.a., Optimedica, Optos, Inc., Optovue., Pelion Surgical, Pfizer Ophthalmics, Quest Medical, Refractec, Reichert, Regeneron Pharmaceuticals, Rhein Medical, Santen, Inc., Scan Optics, Schwind Eye-tech Solutions, ScyFIX, Second Sight, Sirion Holdings, Inc. (formerly Sirion Therapeutics), Sonogage, Sonomed., Stereo Optical Company, Inc., STAAR Surgical, Surmodics, Synemed, Tekia, Titan Surgical, Tomey, Topcon Medical Systems (TMS), Tracey Technologies, Trevi Technology, Visiogen, Inc., Vistakon, Vistakon Pharmaceuticals, LLC, Visual Pathways, WaveLight AG, Welch Allyn, Woodlyn, Inc., and Ziemer Ophthalmic Systems AG.

Ophthalmology 2007 may be purchased here.

Tags: medtech, ophthalmology, refractive, cataract, lasik

See complete MMD report listing here.>

Worldwide Ophthalmology Report from MedMarket Diligence, LLC

Fri, 10 Nov 2006 14:40:57 -0800

Worldwide Ophthalmology Market 2007
MedMarket Diligence has completed a worldwide analysis of the market for devices, drug and diagnostic instrumentation in ophthalmology. The report details the products, technologies, companies and markets per country and/or region for individual western European countries (UK, Germany, France, BeNeLux, Italy and Spain), Japan and other key international markets; Asia (India, Korea, Australia, Russia and China), the Americas (Canada, Mexico, Brazil) and Middle East and Africa categories.

The report is described with a detailed table of contents and list of exhibits here. The report is available for purchase online here.

Tags: medtech, ophthalmology>

The $37 Billion Diabetes Device Market of 2010 (from MedMarkets)

Thu, 2 Nov 2006 10:43:26 -0800

In many developed countries, including the United States, the increase in diabetes prevalence is reaching epidemic proportions. Roughly 250 million patients worldwide are now estimated to have the disorder, a number that is expected to rise to 350 million by 2025. The products, technologies and companies active in the market for diabetes management products are detailed in the October 2006 issue of MedMarkets, and a 2006 report, from MMD.

See coverage in the October issue of MedMarkets. See the MedMarket Diligence report on the Worldwide Diabetes Management Market.

Subscribe online to MedMarkets. Or sign up for a three month trial.

Tags: diabetes, medtech, glucose>

Micro- and Nanomedicine 2006 Report by MMD Praised by Nanotechnology.com Founder

Mon, 9 Oct 2006 06:46:48 -0700

MedMarket Diligence's report on Micro- and Nanomedicine was praised by nanotech investment expert, Darrell Brookstein, who found the report's "analytical work to be exceptional." The founder of The Nanotech Company, LLC, and Nanotechnology.com, Mr. Brookstein writes on and tracks developments in the nanotechnology field.

Below is an excerpt from Mr. Brookstein's Oct. 3 message to his "Best of NanoWeek" subscribers:

Dear Best of the NanoWeek Subscriber,

...

MedMarket Diligence has completed a worldwide business analysis of medically-applied nanotechnologies and MEMS (http://www.mediligence.com/rpt-t625.htm). The report, written for decision-makers in the medical product and investment industries, details the status of technology development, product introduction and actual market penetration of diagnostic and therapeutic applications employing technologies at the micro- and nanoscale. The report applies seasoned industry analysis that is grounded in reality, not hype. The report identifies, describes and focuses in on 100 key companies and details their specific efforts in nanomedicine. The report is a critical resource for participants, investors and others with a stake in micro- and nanomedical product markets. Click here for a complete description of the report and its table of contents: http://www.mediligence.com/rpt-t625.htm.

Folks at my companies, The Nanotech Company, LLC and Nanotechnology.com, find the analytical work to be exceptional and we are already deriving value from its use. I can highly recommend it to anyone who is serious about the field: scientist, entrepreneur, executive or investor.

...

Thanks.

Best regards,

Darrell Brookstein

Tags: nanotech, nanotechnology, MEMS, nanomedicine>

Medical Technologies on the Leading Clinical Edge -- Insights into Emerging Market Medical Opportunities

Thu, 5 Oct 2006 08:01:47 -0700

The most significant developments affecting current and future medical technology markets are revealed at a point that MedMarket Diligence (MMD) calls the "Leading Clinical Edge". Here, the most important clinical trial results emerge, , specific new technologies are evaluated, clinicians explore new techniques and other developments occur that have the potential to dramatically expand, overturn or create medical technology markets. "Leading Clinical Edge" is a regular feature of MedMarkets, from MMD.

Tags: medtech, implant, medical device, medical technology>

Medical Technology Market Outlook for 2007: A Survey by MedMarket Diligence, LLC

Mon, 2 Oct 2006 13:31:28 -0700

The outlook for commercial success in medical technologies in 2007 will be different for different market players. MedMarket Diligence is conducting a brief (5-10 minute) survey of market participants to identify the factors expected to affect this commercial success.

Click here to take the survey.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the MedMarkets newsletter, a monthly analysis of the market implications of new medical technologies, and dedicated reports on technology markets. For additional details, contact Patrick Driscoll at email or call 949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.

Tags: medtech, implant, medical device, FDA, medical technology>

Markets for Surgical Devices for Tumor Ablation (MedMarkets)

Mon, 25 Sep 2006 15:02:28 -0700

Use of ablation technologies for tumor treatment is growing at>25% annual rates, particularly for cryotherapy and radiofrequency ablation, with prostate cancer and liver cancer among the most common applications, according to the September 2006 issue of MedMarkets, from MedMarket Diligence.

See more details in MedMarkets.

-----------
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, ablation, cryotherapy, RF ablation.>

Sample Content from Medical Technology Reports - New XML/RSS Feed

Tue, 5 Sep 2006 14:58:50 -0700

New sample content from MedMarket Diligence's Market and Technology reports will be routinely posted and made accessible at a new rss/xml feed at this link.

See the comprehensive list of MedMarket Diligence Reports.

Tags: medtech>

Ablation and Other Energy-Based Devices in General Surgery (coverage in MedMarkets)

Fri, 18 Aug 2006 14:07:37 -0700

The dynamic market for energy-based devices used in general surgery is growing steadily with short term annual growth rates of 12%, according to the August 2006 issue of MedMarkets from MedMarket Diligence. Consolidation and innovation are two recent industry trends.

See more details in MedMarkets.

-----------
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, biomaterials, orthopedics

MedMarket Outlook: Medical Devices in a Future Scenario

Thu, 17 Aug 2006 10:48:46 -0700

(from August 2006 MedMarkets)

The future of medtech is proceeding along paths determined by technologies already developed, but also guided by the need to provide less invasive treatment of disease with better long-term outcomes. If these paths are followed to their logical endpoint, medical technologies of the future can be predicted. Concurrently, paths toward the development of treatments via biotechnology have their own logical endpoints. Many biotechnologies have the potential to preempt medical technologies, due to their intrinsic design as "rational therapeutics" -- treatments of the root cause of disease rather than only its symptoms.

Here we consider the development in medical technology to have largely achieved its potential and we describe the devices and their characteristics as they would exist in such a future. We make no assertion that each and every technological hurdle that needs to be crossed can indeed be crossed (we imply the possibility); we simply give the benefit of doubt to the technologies that may be developed in order to consider what benefits may ensue.

In short, the future of medtech will be such that two general categories of technologies exist; those that are focused on treating specific pathologies and symptoms and those that represent organs or organ systems. Lastly, it should be noted that we envision this "future scenario" not as one happening 25 years (or more) hence, but in some cases less than a decade.

Disease- and Trauma-Specific Device Solutions
In the idealized future medtech industry, medical devices will have been optimized to facilitate the body's own capacity to heal. Devices will be constructed to provide the function -- e.g., maintaining the patency of a vessel lumen (stents), serving as a temporary or permanent lumen (AAA graft), be a fully functioning hip replacement, etc. -- as long as (and no longer than) necessary for the body to complete all of the repairs of its own that are possible. In this sense, devices will be developed to help the body help itself, then get out of the way to not impede further healing. In particular, bioresorption will have become highly sensitive to timing (stents will dissolve or deconstruct to be excreted at the precise time needed). This will include extracellular matrices used for the regeneration of tissues of all types of tissue (muscle, bone, even nerve) with the matrix facilitating tissue ingrowth before being resorbed. Similarly, biocompatibility will become a more active feature of implanted devices such that they will go well beyond simply being inert or inducing no immunological or other response and will at a maximum, will elute drugs, proteins or other agents that will actively stimulate or facilitate the body's normal healing process.

Devices will be highly intelligent, sensing the conditions in their environment and responding as necessary. Responses will include bioresorption, release of drugs, change in shape or other responses

Devices will be tracked wirelessly for status, providing patient and clinician with information about the status of healing, alerting each to changes requiring intervention long before adverse symptoms appear. This tracking will also include tracking of the device itself, revealing data on device integrity and alerting the patient/clinician to any change.

Increasingly complex devices will be implanted percutaneously, endoscopically or by other means to minimize any trauma. During implantation, the devices will have very low profiles to enable them to traverse to the target site through very small and/or sensitive (e.g., enervated) tissues.

Cost will have played a critical role in determining the effectiveness of device development, but not simply considering the device cost itself, which may be significant. The true cost of these devices will be determined thoroughly as a measure of their ability to achieve specific outcomes compared to the costs of any and all technologies or approaches that compete for similar outcomes.

These device technologies are based on the premise of technologies under development now. Advances in materials technologies, drug/device innovations and many others may produce opportunities for devices with benefits largely unforeseen at this time.

Biohybrid, artificial organs
In light of medtech's general inability to compete directly with the premise of biotech -- treatment of root disease rather than symptoms, medtech will have the potential nonetheless to provide solutions to disease and trauma, with the solutions being ones in which medtech devices or systems so thoroughly address the symptoms of diseases as to emulate cures of them.

In the future world we are envisioning, many organs and organ systems will be available to replace or augment the functions of organs that have been removed or are dysfunctional as a result of disease or trauma. The organs will be comprised of mechanical and biological components that will variously house reservoirs of therapeutics that will periodically and painlessly be replenished, contain bioreactors that will express patient-specific proteins, hormones and other naturally occurring substance, or provide other therapeutic intervention (as with defibrillators, pacemakers, etc.). Mechanical components will be made of materials producing no inflammatory response, inducing no clot formation or other effect and will otherwise be completely neutral to the body.

These organ systems, like the devices described above, will be intelligent, sensing multiple parameters and responding in real-time basis to maintain ideal homeostatic control specific to the patient's dynamic needs (sleep, stress, exercise, metabolism, etc.). The "intelligence" of the systems will be represented in ways from the simple, including elution based on the concentration of substances (platelets, specific proteins, etc.) in the environment (such as to prevent restenosis), to the complex, including microprocessor-calculated basal or bolus infusion of drug or other substance based on biofeedback-mediated function (e.g., insulin pump and glucose monitor).

The status of the biohybrid organ/system will be monitored remotely by the patient and, in turn, by the physician through wireless communication to display current patient condition, trended functions and other status. Eventually, such external monitoring will become unnecessary other than for unusual events, such as extreme changes in patient condition that, even though the organ/system may be well prepared to respond to, warrants attention by the patient and/or clinician.

The biohybrid organ/system status will also be communicated wirelessly, displaying data on its sensor functions, reservoir levels or other parameters of its function, as well as the system's integrity. As with monitoring the organ/system's environment (noted in previous paragraph), the monitoring of the organ/system itself will eventually be silent other than for unusual or adverse events signalling a problem with the system itself.

The power sources employed by these systems will have evolved from being extremely long-term batteries that only infrequently require recharging (done remotely) to motion-activated power (or similar alternative energy sources) to potentially biological sources deriving power from the patient, such as (in a very advanced scenario) through exploitation of energy from adenosine triphosphate (ATP).

Examples of the organs or organ systems that may ultimately be developed (and are in process) include the following:

Pancreas - Glycemic control will be ensured through basal infusion of insulin and periodic bolus matching fluctuating needs. [Based on developments by: Medtronic Minimed, Inc., Smiths Medical MD, etc.]
Heart - Effective replacement of normal heart function will be achieved through designs and construction that will produce no hemolysis, and produce cardiac output precisely matching circulatory need. [Based on developments by: ABIOMED, Inc. Jarvik Heart, Inc., SynCardia Systems, Inc.]
Lung - An artificial lung will largely be achieved through the development of highly effective materials that virtually mimic alveolar epithelium at the interface between lung and blood vessels, enabling efficient gaseous exchange. [Based on developments by MC3, Inc. Novalung GmbH. ALung Technologies, Inc.]
Liver - The myriad functions of the liver will have made it one of the most difficult organs to replace, in effect demanding the development of a master organ with multiple separate organ components addressing the needs of homeostasis (proteins, fat/cholesterol, hormones, vitamins, glucose, etc.), synthesis (proteins, bile acids, cholesterol), storage, excretion, filtering and defensive barrier against bacteria in the gut. The development of biofeedback and control across such multiple areas will be a herculean accomplishment. [Based on developments by Daji Biosciences, Inc. Polygenetics, Inc.]
Kidney - Filtration and regulation of water and inorganic electrolytes in the artifical kidney, by comparison to the development of the artificial liver, will be considerably less challenging. [Based on widespread developments of renal dialysis.]
Skin/integumentary - As an organ system, the integumentary serves an extremely important one in its defense against infection. Artificial integumentary systems may well be developed, although tissue engineering technologies are likely to soon eclipse any artificial technologies.
Limbs - The necessary development of biomechanics and systems to enable autonomic and conscious neural control of limbs may ultimately only be limitated by the strength the patient's healthy anatomy to which it is joined. Fine-motor skills will likely be indistinguishable from biological limbs. Sensitivity to heat and pressure may even be regulated to maximize tolerance of the environment such that performance will exceed that of normal limbs. Overall appearance and in detail will be indistinguishible from normal limbs. [Fundamental technology already widely available; development will continue toward improving the performance and appearance of artificial limbs.]

Selected companies pursuing artificial organ or related development:

3DM, Inc. – Cambridge, MA; http://puramatrix.com
ABIOMED, Inc. – Danvers, MA; http://abiomed.com
ALung Technologies, Inc. Pittsburgh, PA; http://alung.com
Boston Scientific Corporation – Natick, MA; http://bsci.com
Daji Biosciences, Inc. – Graham, NC; no URL
HepaLife Technologies, Inc. – Vancouver, Canada; http://hepalife.com
Jarvik Heart, Inc. – New York, NY; http://jarvikheart.com
Johnson and Johnson -- New Brunswick, NJ; http://jnj.com
MC3, Inc. – Ann Arbor, MI; http://mc3corp.com
Medtronic, Inc. – Minneapolis, MN; http://medtronic.com
MicroCHIPS, Inc. – Bedford, MA; http://mchips.com
Novalung GmbH – Hechingen, Germany; http://novalung.com
Polygenetics, Inc. – Los Gatos, CA; http://polygenetics.com
Smiths Medical MD, Inc. – St. Paul, MN; http://delteccozmo.com
SynCardia Systems, Inc. – Tucson, AZ; http://syncardia.com
VeriChip Corp. – Delray Beach, FL; http://verichipcorp.com

To varying degrees, these developments are already on their way toward completion. And while, indeed, many hurdles remain before some of these scenarios will be possible, one must consider these hurdles in comparison to the hurdles faced by the biotechnology industry as it pursues solutions a variety of diseases and disorders. The "rational therapeutic" holy grail is one that has for biotech been a source of endless promise and endless solicitation of additional venture capital. But as "imperfect" as some of the medtech solutions above may be, their potential as self-contained, cure-like solutions for disease make them eminently more promising for their near-term potential than do "perfect" biotech solutions.

Tags: medtech, biomaterials, orthopedics

----------------------------------------------------------
See MedMarket Diligence Reports: Nanomedicine, Diabetes, Startups 2006, Virtual Reality, Wound Managment, Surgical Sealants

Orthopedic Growth From Biomaterials

Wed, 16 Aug 2006 08:05:36 -0700

The market for orthopedic devices and materials stood at $20 billion worldwide in 2005. Some of its biggest growth is now coming from orthopedic biomaterials, a diverse group of products including grafts, polymers, growth factors, ceramics, tissue engineering products, surgical sealants/glues/hemostats and others. The August 2006 issue of MedMarkets details the products, competitors and market forecast for orthopedic biomaterials.

See more details in MedMarkets.

-----------
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, biomaterials, orthopedics

'Leading Clinical Edge' Feature in MedMarkets Shows Medtech Horizon

Thu, 6 Jul 2006 15:12:49 -0700

"Leading Clinical Edge", a regular feature in MedMarkets from MedMarket Diligence, keeps medtech companies abreast of changes in clinical practice impacting the potential for current and emerging medical technologies. "Leading Clinical Edge" draws upon peer-review journals, clinical trials and other sources to reveal significant changes in the delivery of healthcare that open up opportunities -- and challenges -- for manufacturers .

See more details in MedMarkets.

-----------
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech

Emerging Trends, Technologies and Worldwide Opportunities in Diabetes Market Detailed in 2006 Report from MMD, LLC

Wed, 5 Jul 2006 07:47:03 -0700

Worldwide diabetes market analyzed in report from MMD, LLC.

The diabetes market, which includes both pharmaceuticals and medical devices, is large, and is growing steadily for many reasons. First, the prevalence of diabetes is increasing, particularly that of type 2 in developed countries and those with increasing prosperity. Type 1 diabetes is also increasing, though less dramatically. Second, type 2 diabetes is responsive to drug therapy, and there is a continuing search for newer, better pharmacological agents. Third, insulin, required for all cases of type 1 and some of type 2 diabetes, poses administration problems, offering opportunities for new delivery systems. Fourth, patients with diabetes must monitor their condition by frequently checking the level of glucose in their blood, and there are ongoing attempts to make this process easier and more user-friendly by developing more advanced (and expensive) devices.

A fifth driving factor in the diabetes marketplace is the search for a fundamentally better way to manage the disease. Some options are mainly surgical – transplants of pancreatic cells, for example. Another focus for research is to combine glucose monitoring with insulin administration in a self-controlled wearable device. And farther in the future are prospects for using stem cells to grow new beta cells, and for using genetic knockout techniques to block the metabolic processes that cause diabetes.

__________________________

Other recent Reports from MMD, LLC:

Micro- and Nanomedicine

Startups 2006

See also MedMarkets and the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, diabetes

Drug Delivery Markets to Get Huge Boost from Nanotechnology and MEMS, Details MMD Report

Sat, 1 Jul 2006 06:51:31 -0700

According to a new report from MedMarket Diligence, over 150 companies are active in the field of drug delivery, and a large portion of them are seeking technologies that will result in improved specificity and reduced dose-induced toxicity, which makes the upside for nanotechnology and MEMS in drug delivery an opportunity measured in double-digit growth rates.
__________________________

See also MedMarkets and the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, nanotech, MEMS, drug delivery

Nanotech and MEMS in Medical Applications: Comprehensive Market and Technology Report Released from MedMarket Diligence

Sun, 28 May 2006 10:36:08 -0700

The most extraordinary possibilities of nanotechnology and MEMS (microelectromechanical systems) remain to be developed, yet a $billion+ market already exists for these technologies in biomedical applications, spanning cancer treatment, drug delivery, wound management, sensor technologies, pacemakers, molecular diagnostics, hearing aids and others. The current markets, the current status of development and the emerging and potential markets worldwide are detailed in a new report from MedMarket Diligence.
__________________________

See also MedMarkets and the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, nanotech, MEMS

Nanomedicine Shakes Off Hype, Coverage in May 2006 MedMarkets and New Report from MMD (MedMarket Diligence)

Wed, 17 May 2006 11:57:17 -0700

The potential for nanomedicine, the medical application of nanotechnology, is vast, and has been touted as such almost endlessly since it was conceived. However, already on the market in the U.S. are wound dressings that exploit the antimicrobial properties of nanocrystalline silver, while nanotech-based products for drug delivery, materials technologies and other nanomedical applications are indeed real and in clinical trials now. These findings are presented in the May 2006 issue of MedMarkets, and a forthcoming report from MedMarket Diligence.

__________________________

See "Micro- and Nanomedicine: Technologies, Applications, Industry, and Markets Worldwide", report #T625 (May 2006) detailed here.

See also MedMarkets and the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, nanotech, MEMS

New Competitors in Drug-Eluting Stent Market Seeking to Wrest Share from Boston Scientific, Cordis/J&J, According to April MedMarkets

Tue, 2 May 2006 16:41:08 -0700

The $6 billion global market for drug-eluting stents is poised for new competition from players seeking to tap into a market first dominated by Cordis/J&J and now split by Cordis/J&J and Boston Scientific.

Also in the April issue of MedMarkets, we address critical developments -- product milestones, investment growth, and other key market data -- in the newly optimistic biotech market.

Plus, Startups, Early Stage Companies, Developments, Leading Clinical Edge and other coverage.

__________________________

See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, stents, drug-eluting

White Paper: High Growth Medical Technologies

Wed, 23 Aug 2006 15:34:58 -0700

MedMarket Diligence (MMD) has updated a white paper on select high growth medical technologies based on research across multiple technologies and clinical applications through the company's syndicated Reports business and MedMarkets newsletter.

The paper is also noted at http://medmarkets.blogspot.com/.
__________________________
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech

Emerging Technologies and Worldwide Markets in Diabetes Management

Wed, 22 Mar 2006 14:12:20 -0700

According to a new report from MedMarket Diligence (MMD), diabetes management is facing the emergence of multiple new technologies, from marginal improvement (lancing devices, continuous monitoring, new insulin and antidiabetic drug formulations) to radical shifts (optical glucose sensors, closed-loop monitor/pump systems, stem cells, artificial pancreas). A large marketplace with many competitors and sectors serve the needs of a growing patient population as the large, undiagnosed Type 2 population is steadily penetrated and as other forces (e.g., obesity) continue to drive incidence upward.

__________________________

See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, diabetes, glucose, insulin

Intracranial Endovascular Coils and Microstents, Product Introductions Priming a Growth Market, According to March MedMarkets, from MMD

Fri, 17 Mar 2006 12:05:02 -0700

The market for intracranial endovascular coils and microstents is poised for explosive growth with several new devices being launched within the past few months and several others currently in clinical trials, according to MedMarkets from MedMarket Diligence (MMD).

__________________________

March 2006 coverage in MedMarkets.

See the comprehensive list of MedMarket Diligence Reports.

Applications of Tissue Engineering in Urology - March 2006 MedMarkets

Fri, 17 Mar 2006 11:56:29 -0700

Stress urinary incontinence (UI) and kidney failure, as candidate applications of tissue engineering, are examined in the March 2006 issue of MedMarkets and a market and a technology report from MedMarket Diligence.

_________________________

See coverage in the March 2006 MedMarkets issue.

See also a list of MedMarket Diligence Reports.

Advanced Wound Management Product Usage Increasing Globally and Especially in Select Regional Markets (U.S., Europe, Japan) - Report

Fri, 17 Mar 2006 10:19:01 -0700

Globally, the market for the diverse array of products in surgical, chronic and acute wound management stands at $13 billion, with aggregate growth at 7% annually. Select sectors are demonstrating appreciably stronger growth including active physical stimulation, pharmaceuticals, enzymatic debriders, tissue engineering, and other active therapies for wound management. Differences geographically in the clinical management of wounds and in the adoption of new products are also creating opportunities in local markets. These data are detailed in the newest report by MedMarket Diligence on the worldwide wound management market.

__________________________

See also the comprehensive list of MedMarket Diligence Reports.

Biological Valve Technologies, Minimally Invasive Techniques Bolster Heart Valve Market; High Growth in Sealants, Glues and Anti-Adhesion Market, According to February 2006 MedMarkets

Tue, 21 Feb 2006 08:40:21 -0700

Biological and mechanical heart valves compete in the $1+ billion worldwide market for the treatment of heart valve disease. Products, technologies, competitors and trends detailed in the February 2006 issue of MedMarkets. Also provided is an update on the products, technologies and companies in the markets for surgical sealants, high strength glues and prevention of post-surgical adhesions.

__________________________

February 2006 coverage in MedMarkets.

See also the comprehensive list of MedMarket Diligence Reports.

Bone Graft Use in Europe and the U.S. Dominated by Spine Fusions

Thu, 19 Jan 2006 08:21:45 -0700

With application in many types of orthopedic surgery, the primary application for bone grafts and bone graft substitutes is spine surgery, which accounts for nearly half of all types of bone graft utilization. This is true in both the United States and Western Europe. Details in the January 2006 issue of MedMarkets.

__________________________

January 2006 coverage in MedMarkets.

See Bone Graft Substitutes report details and Spine Surgery Worldwide report details.

See also the comprehensive list of MedMarket Diligence Reports.

U.S. and Western European Bone Graft Substitutes Markets

Thu, 5 Jan 2006 13:45:29 -0700

The markets for bone graft substitutes, one of the more robust growth sectors in orthopaedics, is covered in a report now available from MedMarket Diligence. The U.S. and Western European Bone Graft Substitutes Market report is expected to sustain double digit growth into the next decade.

Coverage in the report includes the detail in the three major segments of the bone graft substitute market: synthetic bone graft substitutes, demineralised bone matrices (DBMs) and bone morphogenic proteins (BMPs), and data is provided on products, markets and competitors in the U.S. and the major countries of Western Europe.

__________________________

See Bone Graft Substitutes report details.

See also a list of MedMarket Diligence Reports.>

Nanomedicine: Small World, Vast Possibilities

Sat, 31 Dec 2005 07:35:24 -0700

Applications of nanotechnology have already been integrated into diagnostic and therapeutic devices. There is intense commercial interest in the medical uses of nanotechnology with at least 100 companies actively involved in this field. The December 2005 issue of MedMarkets details the status of the technologies, products and applications being developed by specific companies.

Subscriber access.

__________________________

See December 2005 MedMarkets.

See also a list of MedMarket Diligence Reports.>

Global Analysis of Diabetes Management Market, 2005-2015

Tue, 13 Dec 2005 07:35:24 -0700

MedMarket Diligence, a highly regarded source of data and insight in medtech markets, has analyzed the $25 billion market for drugs/medications, devices, diagnostics, therapeutics and their combinations in the management of diabetes, with data and insights provided on worldwide and geographic segmentation. The analysis reveals high growth opportunities for manufacturers.

__________________________

See Diabetes report details.

See also a list of other MedMarket Diligence Reports.

Virtual Reality Applications in Surgery and Imaging: Technology and Market Forecast

Fri, 9 Dec 2005 09:49:43 -0700

The global computer-aided surgery market is approximately $465 million and growing rapidly. In the U.S., the computer-aided surgery market was an estimated $296M in 2004. As new companies enter this arena, the annual growth rate is expected to increase from its current level of approximately 10% in 2005 to more than 20% in 2009. The anticipated compound annual growth rate over the forecast period is nearly 16%. While currently systems are primarily used in neurosurgery, developments in surgical navigation systems will facilitate computer-aided surgical systems in other surgical specialties. Chief among these are orthopedics, otolaryngology, cardiac, and spinal surgery. As the technology matures, computer-aided surgery is expected to become standard practice in many specialties, with concomitant improvement in return on investment for hospitals and surgery centers.

The current product offerings, products under development, and their status, are detailed in the U.S. market assessment from MedMarket Diligence covering virtual reality systems targeted to surgery and imaging application.

__________________________

See Virtual Reality report details.

See also a list of other MedMarket Diligence Reports.>

Embolic Protection: Trials, Products and Markets (in November 2005 MedMarkets)

Mon, 28 Nov 2005 09:47:32 -0700

The $1 billion unrealized market for embolic protection is progressively being realized. Trials have demonstrated the needed outcomes and competitors are gaining approvals with products for patients at high risk of stroke.

The clinical trials, product developments and competitor moves in the embolic protection market are reviewed in the November 2005 issue of MedMarkets, from MedMarket Diligence.

See coverage in past issues of MedMarkets.
__________________________

See a list of MedMarket Diligence Reports.>

Drug-Eluting Stents: Off-Label Usage, Competitor Moves

Mon, 28 Nov 2005 09:47:32 -0700

Recent data from the 2005 TCT meeting further reveal the nuances in specific clinical indications favoring different drug-eluting stents (DES). The market continues to evolve nonetheless, with developments from a list of robust competitors.

Clinical trials, product developments and competitor moves are reviewed in the November 2005 issue of MedMarkets, from MedMarket Diligence.

See coverage in past issues of MedMarkets.
__________________________

See a list of MedMarket Diligence Reports.>

Computer-Aided Surgery: Products, Applications and Markets for Virtual Reality in U.S. Markets

Mon, 17 Oct 2005 11:37:06 -0700

Novel Devices for the Treatment of Spinal Disc Disease

Mon, 17 Oct 2005 11:37:06 -0700

Advancements in intraoperative tools, devices and techniques have facilitated minimally invasive surgical approaches to the treatment of spinal disc disease, substantially reducing hospitalization time and improving patient outcomes.

The spinal disc disease treatment market is covered in the October issue of MedMarkets from MedMarket Diligence. The market for spine surgery devices is also covered in the detailed MedMarket Diligence spine surgery report.

*****************************
See coverage in past issues of MedMarkets. Click to subscribe online or via subscription card.>

Growing Market for Obesity Surgical Devices

Mon, 17 Oct 2005 10:38:13 -0700

The rising prevalence of obesity and the lack of significant change in the trend despite the drumbeat of attention on obesity in the press has supported steady growth in the number of gastric bypass and other surgical treatments for obesity. The worldwide market for these obesity surgical devices will grow to over $700 million by 2013.

The obesity treatment device market is covered in the October issue of MedMarkets from MedMarket Diligence. The market for obesity devices is also covered in the detailed MedMarket Diligence worldwide obesity report.

*****************************
See coverage in past issues of MedMarkets. Click to subscribe online or via subscription card.>

Growth in Formation of Medtech Startups, Over 100 Startup Medical Technology Companies Identified in 2005

Wed, 12 Oct 2005 07:56:15 -0700

The number and type of new companies founded in the past 12 months is an encouraging indicator of the growing confidence of entrepreneurs in the medical technology industry. Sample of technologies from startup medtech companies identified in MedMarkets from MedMarket Diligence.

See coverage in past issues. Click to subscribe online or via subscription card.

Endovascular Aortic Aneurysm Repair, Growth from Screening, Devices

Wed, 5 Oct 2005 13:07:18 -0700

A conservative estimate is that 90% of all people with either thoracic or abdominal aortic aneurysms are not aware of the condition. Considering that less than 15% of those whose aneurysms rupture actually survive, there is dramatic opportunity to save lives through increased attention to screening and diagnosis of these aneurysms. And while most of those treated with open surgical procedures to repair their aneurysms have excellent survival rates, the potential to effect repairs substantially less traumatically with endovascular grafts simply increases the opportunity. The clinical trials, available products, products under development and manufacturers are discussed in the September issue of MedMarkets.

Coverage in the September 2005 MedMarkets.

To subscribe via online, download a subscription card or subscribe online.

Virtual Reality in Medicine: Multiple Technologies, Products, Applications, Markets and Opportunities, According to September 2005 MedMarkets from MedMarket Diligence, LLC

Thu, 29 Sep 2005 11:03:21 -0700

The applications for virtual reality in medicine, stemming from advances across the spectrum of imaging and associated technologies, are many and diverse. These encompass medical/dental surgical training, pre-surgical planning, computer-aided surgery systems, interactive 3D diagnostic imaging, radiation treatment, 3D visualization for telemedicine, telesurgery, rehabilitation and sports medicine, neurological evaluation, and more. While the number and type of products are expanding, the economics are changing such that, for example, the price of high performance graphic systems is declining, with a wide number of increasingly affordable products becoming available and driving market growth. The technologies, products, companies, applications and drivers of the market are discussed in the September issue of MedMarkets.

Coverage in the September 2005 MedMarkets.

To subscribe via online, download a subscription card or subscribe online.

Wound Management Market Segments Growing at Rates of Up to 17% Annually in Key Product and Regional Market Areas, According to New Report from MedMarket Diligence, LLC

Thu, 4 Aug 2005 12:33:02 -0700

Globally, the market for the diverse array of products in surgical, chronic and acute wound management stands at $13 billion, with aggregate growth at 7% annually. Select sectors are demonstrating appreciably stronger growth including active physical stimulation, pharmaceuticals, enzymatic debriders, tissue engineering, and other active therapies for wound management. Differences geographically in the clinical management of wounds and in the adoption of new products are also creating opportunities in local markets. These data are detailed in the August 2005 report by MedMarket Diligence on the worldwide wound management market.

The report is detailed here.

The Battleground in Treatment of Coronary Artery Disease

Sat, 9 Jul 2005 13:04:48 -0700

The atherosclerosis market is large, complex, and diverse. It will continue to expand rapidly in many directions over the next 5-10 years, with the explosive rise in global atherosclerosis as the primary market driver.

To subscribe via online, download a subscription card or subscribe online.

Shakeout in the Resynchronization Device Market

Sat, 9 Jul 2005 13:04:48 -0700

The market for implantable cardioverter defibrillators is a growing industry, driven by an increase in the numbers of patients needing resynchronization therapy, primarily due to aging. And yet, not all is rosy in the ICD industry as manufacturers struggle with product failures.

To subscribe via online, download a subscription card or subscribe online.

Medical and Surgical Procedure Volume, Reimbursement and Top Regional Hospitals by Volume Data

Tue, 28 Jun 2005 09:58:21 -0700

Drawing on the coding and reimbursement consulting experience of Medical Technology Partners, MedMarket Diligence introduced in 2004 the TrueData(TM) Reports, a series of data reports presenting procedure volumes, discharges, physician and hospital reimbursement and top volume hospitals by region and generated from expertise in working with multiple datasets from Medicare, the CDC/NCHS, private payer sources and others. Designed as resources to guide decisions about market development in medical technology, each report covers a specific medical/surgical procedure and, depending on the detail clients require, may provide multiple years of data on procedure volume and discharges, physician fee and facility reimbursement and the top hospitals by region in volume of procedures.

Growth and Opportunities for Surgical Sealants, Glues in Wound Closure, Hemostasis

Sat, 25 Jun 2005 07:48:38 -0700

The development of surgical sealants and adhesive, and their increasingly successful role in wound closure, has paralleled the growth of minimally invasive surgery, but sealants have truly succeeded due their versatility in a growing number of procedure types beyond hemostasis of minor wounds. Their use for internal procedures, whether for treatment of traumatic wounds or resections, in which the strength of closure is critical, remains a largely untapped opportunity that is under pursuit by many companies. Cyanoacrylates and other high strength adhesives offer significant growth potential pending resolution of toxicity and other technical challenges. The developments in this area, and the market implications, are covered in the June 2005 issue of MedMarkets, and in a separate report from MedMarket Diligence.

See other Reports from MedMarket Diligence.

Spine Surgery: Detailed Worldwide Data on Procedures, Products, Technologies, Markets & Competitors

patrick@mediligence.com — Wed, 22 Jun 2005 10:42:46 -0700

A recently published report from MedMarket Diligence has garnered significant interest in the spine surgery industry. The report, which covers the global spine surgery market, details procedures, products, technologies, markets and the many companies active in technology and market development in spine surgery.

Bioengineered Skin and Other Tissue Engineered Applications in Wound Management

Fri, 17 Jun 2005 11:41:05 -0700

While tissue engineering, stem cell therapy and other cell therapes are being pursued as solutions for a wide range of diseases and disorders, bioengineered skin, skin grafts and other integumentary applications have already been introduced into clinical applications and as current markets. The untapped potential nonetheless remains very large, with an annual incidence in skin related disorders relevant to tissue engineering worldwide as high as 8 million patients. New applications of bioengineered skin are being developed, especially for diabetic and venous ulcers, and development of these and others in bioengineering of skin is advancing rapidly.

The MedMarket Diligence report, "Worldwide Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, 2004-2014" details the status of product and market development worldwide for skin and other wound management technologies (as well as for technologies in many other clinical specialties).

Incontinence, Kidney Disease the Focus in Urology for Advancements in Tissue Engineering/Cell Therapy

Fri, 17 Jun 2005 11:32:41 -0700

Stress urinary incontinence affects 25 million people in the U.S. alone, driving a $16 billion annual market for products to manage this disease. End Stage Renal Disease (ESRD) affects nearly a half million people in the U.S., and is growing at 8% annually in conjunction with growth in the prevalence of diabetes and hypertension. These two major urological diseases are the focus of intense development in tissue engineering, cell therapy and related technologies.

The MedMarket Diligence report, "Worldwide Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, 2004-2014" details the status of product and market development worldwide in urology (as well as other clinical specialties).

Fracture Fixation, Cartilage Repair, Chondrocyte Transplantation, Bone Graft Substitutes Addressed in Tissue Engineering

Fri, 17 Jun 2005 11:25:07 -0700

In the area of orthopaedics, there are over 5 million annual cases in which tissue engineered solutions are being pursued for a range of conditions. Non-healing fractures, limitation of autologous and homologous tissue supply, opportunities in spinal disc repair, and many other needs in orthopedics have already driven the establishment of orthopaedic applications and markets in tissue engineering.

The MedMarket Diligence report, "Worldwide Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, 2004-2014" details the status of market development in orthopaedics (as well as other clinical specialties) of tissue engineering, cell therapy and related technologies.

Tissue Engineered Solutions to Diseases of Coronary Arteries, Valves, and Peripheral Vasculature, as well as Abdominal Aortic Aneurysm

Fri, 17 Jun 2005 11:15:53 -0700

In the area of cardiology, there are an estimated 19 million annual cases in which tissue engineered solutions are being pursued. Conventional surgical, interventional, drug, device and other approaches to the treatment of these diseases is already an enormous market in the billions annually. The MedMarket Diligence report, "Worldwide Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, 2004-2014" details the status of market development in cardiology (as well as other clinical specialties) of tissue engineering, cell therapy and related technologies.

GERD Moving to Endoscopic Repair

Mon, 23 May 2005 08:37:46 -0700

Limitations in drug treatment due to its long term cost for management of gastroesophageal reflux disease (GERD) or in the cost and invasiveness of open surgical treatment via Nissen fundoplication are driving the market development of endoscopic technologies for treatment of GERD. These developments are reviewed in the May 2005 issue of MedMarkets, published by MedMarket Diligence.

See coverage in past issues of MedMarkets. Then subscribe online or via subscription card.

Stem Cell and Other Cell/Tissue Therapies Succeeding and Driving Investment

Wed, 11 May 2005 11:16:13 -0700

The development of cell-based therapies has been underway for 25 years, working against difficult technical, clinical and market challenges, yet recent successes, such as the use of embryonic stem cells to repair spinal damage in rats (Keirstead et al, Univ. of Calif, Irvine), and pancreatic cell transplants for diabetes, have demonstrated that cell-based therapies are rapidly moving closer to viable clinical (and commercial) applications. Joining the advances already achieved in tissue engineering of skin grafts and orthopedic applications, which are themselves expanding and diversifying, the market for cell and tissue engineered products is realizing the beginnings of its considerable potential. Now, a wide range of technologies are demonstrating proof-of-concept to the degree that they have engendered the continued financial support of the investment industry, the device industry, the pharmaceutical industry and others who remain convinced that the potential rewards of the long R&D process are within a manageable timeline, according to newly completed report by MedMarket Diligence.

The details of the MedMarket Diligence report are provided here.

Nanotechnologies in Medicine

Fri, 29 Apr 2005 07:03:57 -0700

The onslaught of companies claiming to be developing nanotechnologies has burgeoned over the last few years in coordination with the increased availability of federal dollars earmarked for the development of nanotechnologies. While not all of these technologies actually qualify as "nano" and while some may never make it out of the laboratory, there are numerous technologies with potential for real world medical use, according to the April 2005 isssue of MedMarkets, published by MedMarket Diligence.

See coverage in the April 2005 issue of MedMarkets, and other past issues.

MedMarket Diligence has previously provided analysis of nanotechnology & MEMS. See details.

See the complete listing of MedMarket Diligence Reports.>

Growth in the Market for Medical and Surgical Sealants and Glues Remains Robust, According to MedMarket Diligence Report

Sat, 16 Apr 2005 08:54:00 -0700

Since the introduction of surgical sealants and, more recently, surgical glues into medical practice, their use has grown steadily both in the adoption of new medical and surgical applications and steady expansion of caseloads. This market acceptance of the clinical utility of these methods in the closure of surgical and traumatic wounds is driving robust growth in the sales of sealants and glues worldwide, according to a report by MedMarket Diligence.

The MedMarket Diligence report on "The Worldwide Market for Surgical Sealants, Glues and Wound Closure" is detailed at here.

See the complete listing of MedMarket Diligence Reports.

Tissue Engineering & Cell Therapy Continue to Drive Development, Investment, According to New MedMarket Diligence Report

Wed, 13 Apr 2005 09:26:08 -0700

The technologies that have been under development for the engineering of tissues and cell-based therapies for over 25 years continue to face challenges in achieving specific, marketable applications more complex than engineered skin grafts, cartilage and bone. And, despite frequent advances and achievements in the laboratory and the infusion of huge amounts of capital, the bigger challenge for many companies dedicated to tissue engineering and cell therapy is to simply stay in business long enough to commercialize their products. Notwithstanding all of these challenges, many technologies are demonstrating proof-of-concept to the degree that they have engendered the continued financial support of the investment industry, the device industry, the pharmaceutical industry and others who remain convinced that the potential rewards of the long R&D process are within a manageable timeline, according to newly completed report by MedMarket Diligence.

The details of the MedMarket Diligence report are provide here.

The Shift from Spine Fusion to Motion Preservation

Mon, 11 Apr 2005 08:41:00 -0700

Spine fusion technologies continue to represent a viable market in the surgical treatment of degenerative disc disease. The dynamics of the spine and the technical challenges facing alternative treatments, particularly in the face of a large and growing caseload, support these established technologies. However, with the advent of approved alternatives, such as DePuy Spine's Charite, the wholesales shift of spinal surgery from fusion to motion preservation has begun.

The March 2005 issue is available to subscribers only.

The full report by MedMarket Diligence is described in detail.

Spine Surgery Technologies Driving Large Market

Wed, 9 Mar 2005 19:59:59 -0700

The worldwide market for products in spine surgery is poised for strong and sustainable growth through the coming decades as a range of new products, from artificial discs to minimally invasive techniques and a wealth of osteobiologics find their way into a growing medical practice comprised of an active baby boomer population. The worldwide markets for these technologies, and the opportunities emerging, are detailed in a newly published report by MedMarket Diligence.

The report is detailed here.

Bioartificial Liver Assist Technologies

Tue, 15 Feb 2005 09:12:11 -0700

The February 2005 issue of MedMarkets reviews the status of technology developments in bioartificial liver devices, providing an outlook for a $200 million market that may be realized for these devices in the next three years. The article reviews the manufacturers, the status of their technologies and the remaining challenges leading to market introduction. The article on bioartificial liver technologies is drawn from a MedMarket Diligence report on tissue engineering.

Heart Valve Technology Developments

Tue, 15 Feb 2005 09:12:11 -0700

The February 2005 issue of MedMarkets reviews the current developments and market outlook for heart valve technologies, encompassing mechanical valves, tissue valves, annuloplasty and other technologies, including the trend toward percutaneous technologies. The article reviews the leading players and their shares, their current products and their products under development.

Surgical Sealant Market, Applications Proliferate

Tue, 15 Feb 2005 09:12:11 -0700

The market potential for products in the surgical securement field is driven by a combination of new technologies coming to market and expanding application caseloads. The potential for these products will grow steadily over the coming decade as surgical practices improve and the benefits of new products address the requirement for fast and effective closure. A worldwide analysis from MedMarket Diligence details that status of product and market development, the current revenues and shares, and the outlook for the evolving market for fibrin and other sealants, high strength glues (e.g., cyanoacrylates) and other adhesives, and hemostats, and the well established markets for sutures, staples, and tapes, as well as products for prevention of post-surgical adhesion. The report is detailed here.

Products and Markets Worldwide in the Clinical Management of Obesity

Thu, 30 Sep 2004 00:00:00 -0700

The market potential for products in the clinical management of obesity continues to center on surgical treatments (e.g., gastric bypass, stapling, lap band, etc.), yet new developments including drugs may well displace surgical approaches and expand the caseload of patients treated for obesity. The report is detailed here.

European Cardiac Surgeon Survey on Practices, Products and Future of Coronary Artery Bypass Grafting

Thu, 10 Feb 2005 09:12:11 -0700

This Clinical Insight Brief from MedMarket Diligence is a summary and presentation of findings from interviews with 25 European cardiac surgeons regarding their current practices, caseload and perspectives in the performance of coronary artery bypass grafting (CABG), as well as their opinions on emerging practices and technologies for CABG including the use of off-pump (also known as "beating heart") bypass, minimally invasive direct coronary artery bypass (MIDCAB) and the specific products available or under development by manufacturers for these purposes. Direct phone interviews were held with cardiac surgeons in August/September 2004. The report is detailed here.

Current Awareness in the Clinical Understanding of Cardiovascular Disease, the Options for Treatment and the Outlook for Cardiovascular Diagnostics and Therapeutics

Thu, 10 Feb 2005 09:12:11 -0700

Atherosclerotic vascular disease is among the most frequent causes of death worldwide. It is the consequence of complex interactions between many pathogenic mechanisms including alterations in lipoprotein metabolism, fibrinolysis, coagulation, and vessel-wall structure. Current therapeutic strategies have historically concentrated mainly on lowering low-density lipoprotein (LDL) cholesterol and an impressive reduction in the risk for cardiovascular morbidity and mortality has been achieved. Inflammatory mechanisms are more and more recognized to play an important role in vascular disease as inflammatory markers correlate with prognosis in acute and chronic coronary artery disease. This shift in focus comes as a byproduct of extensive research in vascular biology which has clearly demonstrated that inflammation can play a vital role in the initiation, maintenance and/or progression of atherosclerosis. This MedMarket Diligence study captures the state of clinical understanding and the implications for atherosclerosis diagnosis and treatment. The report is detailed here.

MedMarket Diligence and Medical Technology Partners Release Report on the Top Volume Cardiovascular Inpatient and Outpatient Discharges by Age, Payer and Region

Thu, 10 Feb 2005 09:12:11 -0700

This report presents detailed inpatient and outpatient procedure data on the highest volume cardiovascular procedures. The data in this report has been an invaluable component of analyses by MedMarket Diligence in its cardiovascular device technology analyses, and is now available as a separate report produced in conjunction with Medical Technology Partners. The report presents a ranking of the top cardiovascular procedures by volume, with detailed data from Medicare, the National Hospital Discharge Survey, the Healthcare Cost and Utilization Project, Data is presented on discharges by payer (Medicare, Medicaid, Blue Cross/Blue Shield, other private insurance, self-pay, no charge, uninsured, other), age group (<1, 1-17, 18-44, 45-64, 65-84 and >85) and U.S. geographic region (midwest, northeast, south, west). The report is detailed here.

Medical, Surgical Procedure Volume, Reimbursement, Top Volume Hospital Data from MedMarket Diligence and Medical Technology Partners

Tue, 15 Feb 2005 09:12:11 -0700

Drawing on the coding and reimbursement consulting experience of Medical Technology Partners, a highly respected industry resource, MedMarket Diligence has introduced TrueData(TM) Reports, a series of data reports presenting procedure volumes, discharges, physician and hospital reimbursement and top volume hospitals by region. Designed as resources to guide decisions about market development in medical technology, each report covers a specific medical/surgical procedure and, depending on the detail clients require, may provide multiple years of data on procedure volume and discharges, physician fee and facility reimbursement and the top hospitals by region in volume of procedures.

Heart Failure the Target of Multiple Management Approaches

Mon, 31 May 2004 12:39:26 -0700

Nearly five million people in the U.S. suffer with heart failure, the inability of the heart to pump sufficient blood, and over 400,000 patients are newly diagnosed each year, but improvements in understanding, development of therapeutics and overall management of heart failure is creating dramatic progress, according to a new report, "Products, Systems and Opportunities in Heart Failure Management," from MedMarket Diligence. Details on the report are available here.